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ABSTRACT 
RAFEEQUE, SHIFA, AMEENA, Masters of Science: January: 2020, Public Health 
Title: The effect of Renin angiotensin system blockers versus calcium channel blockers on 
progression towards hypertensive chronic kidney disease: A comprehensive systematic 
review based on Randomized controlled trials 
Supervisor of Thesis: Mohammed Fasihul Alam. 
Background: 
Decline in estimated Glomerular filtration rate (eGFR) is associated with further 
progression of chronic kidney disease. Evidence suggests that Renin Angiotensin System 
blockers (RAS), which can be angiotensin-receptor blockers (ARBs) or Angiotensin 
converting enzymes Inhibitors (ACEIs), have reno- protective effect, but results are 
variable. Similarly, effects of Calcium channel blockers (CCBs) are shown to have a role 
in protecting renal function but differ across studies. Hence, the relative effect of ARBs or 
ACEIs as well as CCBs, and their administration as monotherapy, remain uncertain. 
Purpose: 
To summarize and determine the pooled effect of RAS versus CCBs on progression 
towards hypertensive CKD amongst diabetic as well as non-diabetic patients with CKD of 
any stage from I-IV.  
Data Sources: 
All language studies in PubMed, the Cochrane Library Central, Clinical Registry of 
unpublished Trials, WHO, Embase, Scopus, ProQuest, reference lists, and expert contacts 
up to September 2019. 
Study Selection: 
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This study included all the full text articles that studied diabetic and non-diabetic patients 
with eGFR ≥ 15 ml/min per 1.73m3 or Urinary albumin excretion levels (UAE) ≤ 300mg/d 
during RAS based treatment an intervention in direct comparison with CCBs treatment 
based approach as comparator at baseline and at the end of follow-up. However, pooling 
of all the included studies using meta-analysis was not feasible due to substantial study 
heterogeneity and the small number of included studies that are meta-analyzable. So, 
studies were selected for systematic review, and out of which, all the meta-analyzable 
studies were quantitatively analyzed on the basis of main outcomes such as (i) Relative risk 
for CKD progression and (ii) Mean differences in SBP and DBP for both the arms. Doi 
plot and funnel plot were used for detection of publication bias. 
Results: 
Review with seven included trials, and meta-analysis using IVhet model was done on three 
studies for primary CKD outcome and four studies for secondary BP outcomes. RAS 
blockers and CCBs did not show any statistically significant differences in terms of its 
effects on further progression CKD with RR of 0.90 [95% CI 0.69, 1.16]. Moreover, there 
was no statistically significant difference in BP from baseline to final end points between 
CCBs and RAS inhibitors with WMD of -2.09 mmHg [95%  CI -5.96, 1.79] for mean SBP 
change and -0.71 mmHg [95% CI -2.16, 0.73] for mean DBP change.  
Conclusion: 
Evidence asserts no difference between RAS and CCB concerning the risk of progression 
for CKD and in terms of mean BP differences. However, the study have its own set of 
limitations due to which more well designed and well conducted RCTs with robust findings 
are required to confirm the inferences based on this review. 
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CHAPTER –1: INTRODUCTION 
According to World Health Organization, nearly 1 in 4 adults have HTN across 
developing and developed nations (1).  The burden of HTN at global level accounts for 7.5 
million deaths equivalent to about 12.8% of all deaths and 57 million Disability Adjusted 
Life years (DALYs), which is equivalent to 3.7% of total DALYS (2,3). It was estimated 
that overall epidemiological burden for the adults aged ≥ 25 are equivalent to 40% in 2008 
(4). The proportion of patients with HTN worldwide increased from 600mn in 1980 to 
nearly 1 billion in 2008 due to ageing and population growth (3). Amongst the WHO 
regions, the prevalence of HTN (in both male and female) is found to be the highest in 
Africa (46%) and the lowest in America (35%) (1,3). 
HTN is a significant risk factor for cardiovascular disease and plays an eminent role 
in contributing to the incidence of chronic heart disease, stroke and kidney failure (5). 
Uncontrolled BP can also cause vascular dementia, peripheral artery disease, aneurysms as 
well as eye damage (1). Although Chronic Kidney Disease (CKD) is one of the byproducts 
of HTN, diabetes and family history which are responsible for 2 in 3 of the CKD cases, it 
is reciprocal as it can cause HTN as well (6). There is no solid evidence that CKD can be 
reversed, due to which it is vital to diagnose early for preventing its exacerbation (7). 
HTN has been tackled in various ways and the pharmacological therapeutic choices 
are divided into five major classes of drugs (8). They are: (1) Calcium channel blockers 
(CCBs)  such as Amlodipine (Norvasc), Diltiazem, Felodipine, Isradipine, Nicardipine, 
Nifedipine, Nisoldipine, Verapamil; (2) Angiotensin‐converting enzyme inhibitors 
(ACEIs) such as Perindopril, Ramipril, Captopril, benazepril, trandolapril, fosinopril, 
Lisinopril, moexipril, enalapril; (3)Angiotensin II receptor blockers (ARBs) such as 
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Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan and 
valsartan; (4) Βeta-blockers (BBs) such as Acebutolol, atenolol, betaxolol, bisoprolol, 
metoprolol, nadolol, propranolol, timolol, and (5) Thiazide type Diuretics such as 
Chlorthalidone, hydrochlorothiazide, metolazone, indapamide (5).  
Furthermore, ACE inhibitors and ARBs are commonly called Renin Angiotensin 
System (RAS) blockers which is also known as Renin Angiotensin Aldosterone System 
(RAAS) blockers, because of the functions of ACE inhibitors and ARBs (9,10). ACE 
inhibitors usually inhibit the renin angiotensin I from forming into more potent angiotensin 
II which can narrow the blood vessels and likewise, ARBs inhibits angiotensin II from 
binding on its receptors (11,12). According to American Diabetes Association guidelines, 
these RAS blockers are considered as the first line treatment for those with HTN (13,14) 
Recently done trials has shown that BP lowering capacity by RAS blockers has 
benefit of renal protection in diabetic and non-diabetic kidney diseases and specifically in 
non-diabetic patients, studies such as AIPRI and REIN trials confirm the added long term 
reno-protective effect by use of ACE inhibitors (Wolf &Risler, 2004). Studies also 
advocate that CCBs and ACE inhibitors have a synergistic effect on BP control and CVDs 
(16). Consequently, it has been shown that if it is used appropriately, it can result in better 
health outcomes including Reno-protective effect (16–18). Guidelines had placed both 
CCB and RAS at same levels as initial therapies in patients with HTN without compelling 
indications; like diabetes or established CAD, stroke or CKD; with preference of CCB in 
blacks and elderly as more efficacious than other drugs (19). 
In addition to above mentioned individual studies, there are several Systematic 
reviews and meta-analysis on the effects of either RAS blockers, CCBs or both on the 
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progression towards CKD (20–22). Moreover, several other studies linked across all 
antihypertensive drugs and its effect on renal outcomes (22–25). Some of them focused 
on either of the RAS blockers such as ARBs or ACEis and its progression towards CKD 
(22,26–31). These studies encompassed effect of renal disease progression amongst those 
with diabetes as well as non-diabetes. On the other hand, there are several other systematic 
reviews and meta-analysis that emphasized on the effect of CCBs on CKD outcomes 
(32,33).  
Besides, some of the systematic reviews and meta-analysis were covering RAS blockers 
in direct comparison with CCBs and its effects on renal outcomes (34–37). Out of those 
four SR and MA that were done in the similar topic, two of them found that there were no 
significant differences between RAS blockers and CCBs in terms of renal and blood 
pressure outcomes in addition various other outcomes including stroke, heart failure, 
cerebrovascular events and all cause mortality (34,35). However, two other very recent 
ones showed that RAS is superior over CCB for retarding the progression towards CKD 
and reducing blood pressure (36,37). Nonetheless, all of these studies are quite distinct 
due to discrepancies in the study PICO from the existing literature. For instance, two of 
the recent meta-analysis, which was similar in title but different by the population group 
as they covered only diabetic and CKD Stage 3-5 patients (34).   As for clinical trials 
with direct comparison, majority of them showed that RAS blocker are more effective in 
slower progression of CKD except two trials. (38–42). On the other hand, one of those 
two trials showed similar renal outcomes in both the arms while the other one showed that 
CCB is superior to RAS blockers.  
Despite a number of studies and clinical trials are conducted to investigate the 
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effectiveness of all classes of hypertensive drugs in terms of CKD, CVDs and mortality 
outcomes, unparalalled  evidence on the actual impact of RAS blockers versus Calcium 
channel blockers based treatment approach on the decline in estimated GFRor increase in 
UAE for all the hypertensive patients with any CKD stage from I-IV (eGFR≥15 
ml/min/1.73m2 or UAE<300 mg/d) amongst diabetes as well as non-diabetics (43). 
1.1. Aim:  
To study the relative effect of any Renin angiotensin system blockers (RAS) and any 
Calcium channel blockers as monotherapy amongst non-diabetic as well as diabetic 
patients with  any CKD stage from 1-4 based on the further decline in eGFR or rise in 
Urinary albumin excretion levels than at the baseline. 
1.2. Objectives: 
• To examine the relative risk for progression towards decline in eGFR or rise in 
Urinary albumin excretion levels with RAS blockers (ACE inhibitors or ARBs) 
compared to any CCB as an initial therapy amongst  non-diabetic as well as 
diabetic hypertensive CKD patients. 
• To investigate the effect of Renin Angiotensin System blockers (RAS) and 
Calcium Channel Blockers (CCBs) based monotherapies on BP control 
(SBP/DBP) by pooling mean differences in SBP and DBP. 
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CHAPTER –2: LITERATURE REVIEW 
2.1. Burden of HTN: 
According National Institute of Health, one in three adults in US have HTN and it 
is known as silent killer as it can occur without showing any apparent symptoms (44). Due 
to its asymptomatic nature, if it is left undiagnosed or untreated, it can place one at greater 
risk of developing cardiovascular diseases (CVDs) including stroke, heart failure (HF), 
heart attack (HA) as well as vision loss, CKD or failure, and sexual dysfunction(45–47).  
As per projections from NHANES in 2013, prevalence of high BP in the US, will 
increase 7.2% by the year of 2030. It was found that until the age of 45, men have more 
burden of HTN than women, followed by similar burden across both the genders between 
45-65 years of age and, when the age increases over 65, a higher percentage of women 
have more prevalence compared to men (4,48).  
According to the American Heart Association (AHA) in 2009, 44.8% of male 
deaths and 55.2% of female deaths were caused due to HTN in the US (48). It was 
estimated that from 1999 to 2009, there had been an increase by 17.9% in terms of death 
rates from HTN and the actual number of deaths was found to have risen by 43.6%. As for 
the economic burden of high blood pressure, it was shown as 51.9 billion dollars in the 
year 2009 (4).  
2.2. Burden of CKD: 
 According to Center for Disease Control and Prevention (CDC), nearly one in three 
adults with diabetes and almost one in five adults with HTN are likely to have CKD (49). 
It was shown that CKD were of high chances when they had hypertension, diabetes or 
family history(43). When a person is suspected to have decreased renal functions, fluids 
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accumulate in the body causing excess fluids in the lungs resulting in HTN (50,51).  
Studies shows that around 30 million people in United States are having CKD. 
There are around 48% of those with severely poor renal function do not undergo dialysis 
are unknown about their CKD Status. Almost every person with mild or moderately poor 
renal function are unaware of the presence of CKD (51). Studies also indicate that 
prevalence of CKD is more among women (16%) than in men (13%) in US (50).  
According to CDC, risk of premature death from heart disease as well as all-cause 
mortality is higher in patients with CKD compared to those without (51). However, for 
end-stage renal disease in which eGFR drops below 15 ml/min/1.73 m2, men are found to 
have more likelihood than women and African Americans had more risk than whites in US 
(43,52).  
 There are multiple studies that indicate the advantages of controlling BP in patients 
with and without renal disease including slowed progression of CKD and reduction in risk 
of developing cardiovascular disease as well as mortality (53). Patients with and without 
diabetic CKD also known as nephropathy with decline in eGFR than normal level of higher 
than 90 ml/min/1.73 m2 or the presence of proteinuria are shown to benefit particularly 
from pharmacological approach with RAS blockers using ACE inhibitors or ARBs (53).  
2.3. Antihypertensive treatment regimens on CKD and BP control: 
In terms of Antihypertensive drugs, ARBs and ACEis are commonly known to be 
the best of medications for treating HTN as well as due to its independent effect on CVD, 
CKD and mortality outcomes(19). Several other studies also confirmed that Telmisartan, a 
type of ARBs and ACEis are highly effective as well as widely prescribed as 
antihypertensive drugs due to its efficacy and safety profile (54,55). However, many large 
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studies including meta-analysis have showed that ARBs are sometimes considered to be 
superior than ACEis with fewer adverse events such as dry persistent cough unlike ACEis 
(47,54–58). Nevertheless, ACEis are well tolerated as well and was considered to be the 
first line treatment by various guidelines due to reduced risk of having CKDs, CVDs and 
Myocardial infarction associated with ACEis (59).  
On the other hand, ARBs are known to be costly than ACEis, although these days, 
ARBs are made available as generic drug which makes the cost difference minimal(19). 
However, based on numerous studies, both are still recommended equally as they both stay 
highly superior in terms of its favourable effects (19,60,61).   
As for CCBs, various systematic reviews and meta-analysis has shown that 
amlodipine, a type of calcium channel blockers is beneficial in BP control as well as in 
protecting against various major complications including CVD and CKD outcomes 
(32,62,63). Moreover, several significant guidelines also recommend CCBs and RAS 
blockers including ACEis and ARBs in treating HTN and preventing various major 
consequences (19,60). 
Based on previous studies, guidelines recommend either of RAS based therapy for 
the patients with nephropathy and without CKDs but has higher risk of developing renal 
impairment due to diabetes, abnormal level of micro albumin in urine and HTN as ACEis 
and ARBs has highly superior Reno-protective effects compared to other antihypertensive 
drugs (64).  
Findings based on a large meta-analysis of eleven clinical trials with sample size of 
84, 363 patients, demonstrated that RAS blockers including ACEis or ARBs, must be 
recommended in patients who has high risk of new onset of diabetes (NOD) as these are 
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helpful in reducing the incidence of NOD and in having desirable effects in Cardiovascular 
with OR and non-cardiovascular mortality  amongst those patients with high risk for CVDs 
(65). 
In addition, numerous clinical trials has indicated that RAS has a significant role in 
protecting renal function along lowering of BP amongst both diabetic as well as non-
diabetic patients with renal diseases due to the antiproteinuric action of RAS (66). 
On the contrary, based on an ecological study, it is shown that ARBs and ACEis are 
the most commonly prescribed medication for high blood pressure, heart and kidney 
diseases for people with and without diabetes, and there was an increase kidney problems 
with increasing prescription of RAS blockers which could potentially be due to lack of 
patient level data (67,68). 
Some studies comparing CCBs to RAS blockers stated that their effects are similar in 
terms of protecting against major complications except that RAS blockers are particularly 
superior in case of reducing risk of heart failure (13). However, the majority of the 
recommendation from guidelines considers RAS blockers as a better first line therapy for 
non-diabetic CKD patients (69). 
Concerning RAS blockers’ impact on CKD outcomes, there are several systematic 
reviews or/and meta-analysis that have been done previously. One of the meta analysis 
that looked at progression of CKD and its association with the factors such as BP control 
and lower UAE during antihypertensive therapy with or without ACEi, had found that 
SBP control between 110-129mmHg as well as UAE <2.0 g/d have association with 
lowest risk for progression of CKD. However, the study also tried to estimate the risk after 
adjusting for these factors and RR was shown to be 0.67 [95% CI of 0.53-0.84] (21). 
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Moreover, systematic review showed that ACEi and ARB are being beneficial for treating 
CKD in Albuminuric patients with diabetes or CVD (28).  
 Another meta-analysis that looked at the effect of ACEi on progression of non-
diabetic renal disease had found that HTN treatment regimens that included ACEi was 
effective in controlling BP as well as for delaying renal disease progression (70). The 
mean decrease in SBP as well as DBP was by 4.5 mmHg [95%CI of 3.0 to 6.1mmHg] and 
2.3 mmHg [95% CI of 1.4 to 3.2 mmHg] respectively in addition to mean in UAE level 
by 0.46g/d [95%CI of 0.33 to 0.59 g/d]. After adjusting for baseline factors including 
changes in BP and UAE levels, ACEi had demonstrated more protective effect in slowing 
down the progression of CKD towards stage V with RR of 0.69 [95% CI of 0.51-0.94]. 
Moreover, it was noticed that patients with baseline UAE levels ≥ 0.5 g/d were more 
advantageous of ACEi therapy. However, study added that their data were inconclusive to 
suggest whether benefit of ACEi therapy remained same for the patients with baseline 
UAE levels <0.5 g/d. 
Another meta-analysis of randomized controlled trials on the effect of ACEi for 
the non-diabetic renal disease progression indicated that,BP that was evidently controlled 
by ACEi. Also, it was shown to have reduced risk for end stage renal disease as well as 
mortality with RR of 0.70 [95% CI of 0.51 to 0.97] and RR of 1.24 [95% CI of 0.55 to 
2.83] respectively (71). The study concluded that ACEi are greatly effective than any other 
antihypertensive treatment regimens. However, they could not determine if this effect was 
mediated by its effect on BP or any other related factors. 
One of the systematic review and meta-analysis that compared RAS blockers such 
as ARB/ACEi with other antihypertensive drugs on kidney outcomes, has shown that there 
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was only small benefit in terms of progression towards CKD Stage V with RR of 0.87 
[95%CI of 0.75 to 0.99] (27). The study indicated that the benefit of ACEi/ARB on renal 
outcome is resultant of its BP lowering effect. However, the study also added that the 
additional Renoprotective actions of these treatment regimens beyond BP control in 
diabetic renal disease patients remains unproven. Moreover, they stated there is 
uncertainty about greater Renoprotective effects seen among non-diabetic renal disease  
patients. Last but not least, they also stated that placebo controlled trials of ACEi/ARBs 
showed greater reduction in progression of CKD than those trials that compared 
ACE/ARBs with other antihypertensive drugs. 
According to CASE-J and several other trials, it also indicated that RAS blockers 
play an essential role in pathological process of elevated blood pressure, kidney and cardiac 
diseases (40–42) . Besides that, many trials suggest that ARB as a RAS inhibitor is a quite 
protective first line therapy in diabetic and non-diabetic patients(72–74).  
Nonetheless, CCBs as a therapy in the progression of CKD was found to 
contradicting findings as some trials supporting that it is beneficial while some states that 
it has no benefit(38,75–77). One of the existing study indicated that CCB is not beneficial 
in lowering BP and had OR of 1.67 [95% CI of 1.22 to 2.28] for microalbuminuria but 
favored RAS blockers on its effect in BP control and microalbuminuria with OR of 0.99 
[95% CI of 0.73 to 1.35] (78). 
 Based on several CKD based trials, RAS blockers were known to reduce UAE by 
35-40% compared to other antihypertensive drugs after adjusting for BP control effect. 
However, CCBs were found to have variation in its effects as some studies indicated that 
Non-dihydropyridine CCBs can be effective for BP control amongst diabetic patients in 
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comparison to other type of CCBs such as dihydropyridine agents. Lately, studies as well 
as NICE guidelines showed that CCBs are specifically better in terms of effects for African 
Americans (19,79). 
  Besides, several clinical trials had made comparison between RAS antagonists and 
CCBs in particular. One of the biggest trial by ALLHAT indicate that renal events are 
similar in both the arms with RR of 0.99 [95% CI 0.77, 1.26] (41). Multiple studies 
comparing CCB vs ACEi based regimens found no differences in rate of decline in GFR 
between either of the drug or BP control groups.  Another study comparing ARB vs CCB 
also had shown the same result in terms of GFR reduction (80,81). Moreover, several 
significant guidelines also recommend CCBs and RAS blockers including ACEis and 
ARBs in treating hypertension and preventing various major consequences (19,60). 
Another trial has shown no statistically significant risk reduction between ARB and CCB 
with HR of 0.40 [95% CI 0.13, 1.29] (42). However, one of the major trials by AASK 
revealed that there is 38% risk reduction in ACEi group compared to those in CCB [95% 
CI 10, 58](38).  
Another indicated that the proportion of those who had normal albumin status after 
being microalbuminuric at baseline were relatively higher in ACEi group (46%) than CCB 
arm (33%) (40). Also, eGFR reduction was found to be higher in ACEi group than CCB 
based on Nephros and ALLHAT study (39,41). Another study has shown that UAE levels 
reduction was greater in CCB (Mean change in UAE level of 9.49 mg/d) over ARB group 
(Mean change in UAE level of 0.29mg/d) (82).  
  In regard to SR and MA in this context, a recent meta-analysis that had direct head 
to head comparison indicated that CCBs has higher probability of having renal events 
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compared to RAS with OR of 1.25 [95% CI, 1.05–1.48] among CKD patients (35). 
Meanwhile,  another study published this year has shown that there is no statistically 
significant mean difference between CCBs and ACEi with regard to BP, UAE levels as 
well as GFR of diabetic CKD (37). Similar was the finding based on a study that was 
published earlier with RR of 1.14 [95% CI, 0.95-1.37] (34). All of these trials had implied 
similar BP reduction in both the groups (38–42,80,82).  
  All of these inconsistent results based on numerous studies considering the burden 
of CKD and the fact that CKD is irreversible, were the driving force behind the rationale 
of this study as it is important to understand if both of treatments stands equally in 
achieving better renal outcomes. 
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CHAPTER –3: METHODS 
3.1. Study design 
 A systematic review and Meta-analysis of randomized controlled trials 
3.2. Search Strategy 
3.2.1. Data sources 
The sources of the data for this study are (a) Electronic databases such as PubMed, 
the Cochrane Library Central, WHO, Embase, Scopus and ProQuest, (b) Grey Literature 
such as  Clinical Registry of unpublished Trials, International Clinical Trials Registry 
Platform (ICTRP) and Open Grey, and (c) hand search of reference lists including 
backward as well as forward citation search and (d) expert contact up to September 2019, 
for relevant articles in all languages by using the Keywords and synonyms as given below. 
I also used MeSH terms for PubMed.  
I screened the reference lists of included studies and related publications, and 
corresponding authors were contacted for clarifications regarding the relevant articles that 
had potential for inclusion. For instance, As for large studies by Research study groups 
such as AASK and ALLHAT had done multiple trials over the years that used same 
population but not clearly mentioned in the trial, its authors were contacted to confirm 
population group they employed and asked them if they used same kind of population but 
from different locality, in which case, studies can be eligible. These were required to be 
understood to make a decision on selection of such trials because if it is found to be same 
population, it is not possible to include more than one trial by AASK or ALLHAT. Also, 
some of the authors were contacted for the purpose of retrieving the data that I need as it 
was not mentioned in the study. In addition, I had looked for existing meta-analyses and 
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systematic reviews in the context of antihypertensive drugs and its impact on CKD 
outcomes, to ensure that no studies, that meets criteria, were missed out during study 
selection from the above-mentioned data sources. 
3.2.2. Search terms 
Table 1: Keywords used in the search engines 
Population Intervention Comparator Outcome 
HTN , high BP , 
elevated blood 
pressure 
Angiotensin-
receptor-blockers, 
arbs, losartan, 
valsartan, 
irbesartan, 
candesartan, 
telmisartan, 
eprosartan, 
olmesartan, 
Angiotensin‐
converting enzyme 
inhibitors*, aceis, 
perindopril, 
ramipril, captopril, 
benazepril, 
trandolapril, 
fosinopril, 
lisinopril, 
moexipril, enalapril 
Calcium channel 
blockers, ccbs, 
amlodipine, 
diltiazem, 
felodipine, 
isradipine, 
nicardipine, 
nifedipine, 
nisoldipine, 
Lercadipine , 
verapamil , 
diltiazem 
Glomerular filtration 
rate, GFR, 
proteinuria, 
microalbuminuria, 
urinary excretion 
levels, non-diabetic 
nephropathies, renal 
impairment , renal 
failure, stage 3 
chronic kidney 
disease, stage 4 
chronic kidney 
disease, stage 5 
chronic kidney 
disease*, CKD*, 
Chronic kidney 
disease* 
    
 
3.2.3. Search String(s) 
The search thread used for screening title or abstracts was angiotensin converting 
enzyme inhibitor* OR Perindopril OR Ramipril OR Captopril OR benazepril OR 
trandolapril OR fosinopril OR Lisinopril OR moexipril OR enalapril OR angiotensin 
recptor blocker* OR losartan OR valsartan OR irbesartan OR candesartan OR telmisartan 
OR eprosartan OR olmesartan AND calcium channel blocker* OR Amlodipine OR 
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Diltiazem OR Felodipine OR Isradipine OR Nicardipine OR Nifedipine OR Nisoldipine 
OR lercadipine OR Verapamil OR diltiazem AND Glomerular filtration rate OR GFR OR 
CKD OR Chronic kidney disease* OR nephroprathies OR renal impairment OR proteinuria 
OR Albuminuria.   
Search restriction were none but humans based studies. Also, primarily I focused 
retrieving only experimental studies as I was aiming to do Meta-analysis and ended up with 
3-4 studies that were meta-analyzable. However, since Meta-Analysis of less than 5 studies 
is not preferable due to flawed error estimation, I included studies that were not meta-
analyzable in terms of CKD measures to pool more studies with an aim to do Systematic 
review alone (83). 
Some of the major databases along with search strings that were used in retrieving 
the relatively relevant articles from three of the major databases are given in Appendix A, 
to enable replication by other researchers. 
3.3. Study Selection 
This study has a well-defined PICO based on which the set of eligibility criteria, 
were followed and met. In our study, the population (P) are non-diabetic as well as diabetic 
hypertensive adults aged ≥18 years with CKD of any Stage except V, I (Intervention) as 
RAS blockers based treatment approach (ACE inhibitors or ARBs), C (Comparator) as 
CCB based treatment approach, and O (Outcome) as progression towards further CKD in 
terms of further reduction in estimated glomerular filtration rate (eGFR)or added increase 
in UAE levels than at the baseline. In terms of treatment strategies, the studies must be 
looking at a single pill therapy for both RAS blockers as well as CCBs. 
The inclusion criteria had included all the full text articles that studied non-diabetic 
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and/or diabetic hypertensive patients with either eGFR ≥ 15ml/min/1.73 m2 or UAE ≤ 
300mg/d during RAS based treatment approach in direct comparison with calcium channel 
blockers treatment based approach. Thereby, I included patients with and without CKD 
(Stage I-IV) to discern the progression of CKD in terms of decline in GFR and increase in 
UAE than at the baseline after taking the medications. 
In other words, aim was to assess those studies that begin with RAS blockers based 
monotherapy or any add on other than CCBs as well as any CCB based monotherapy that 
had any add on other than any of RAS blockers amongst non-diabetic and diabetic adults 
aged ≥18 with eGFR ≥15 ml/min/1.73 m2 or UAE ≤ 300mg/d. Moreover, included studies 
must have direct head-to-head comparison between intervention and comparator and must 
not be of less than 3 months in terms of patients’ follow-up. 
This study had excluded those studies that had patients with renal transplantation, 
any degree of abnormal urinary protein excretion of more than 300mg/d or reduced eGFR 
of less than 15 ml/min per 1.73m2, duration of less than 3 months, and the ones who had 
undergone dialysis and pregnant women. Pregnant women are excluded as their 
management of HTN varies from that of a normal adult in general and according to NKF, 
pregnant women should not be included in antihypertensive drug based trials as it can 
negatively affect the fetus (79,84). I chose 3 months as minimum study duration because 
according to American Society of Nephrology (2011) and National Kidney Foundation 
(2004), it was mentioned that initiation of study medication can take 3-4 months to show 
decrease in renal function depending on the GFR observed at the baseline (79).  
Moreover, the studies with RAS based combination therapy, to which any CCB 
was being added or vice versa, were excluded, as that could potentially confound the actual 
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impact of each monotherapy. Concomitantly, the studies that had any RAS based first line 
monotherapy, which was later combined by either of RAS blockers, were excluded. As a 
matter of fact, there were a large number of studies that indicated that ARBs in combination 
with ACEis has very limited and contradicting evidence on the safety and efficacy in regard 
to combining these two prominent antihypertensive drugs (10).  In addition, various 
international guidelines on medication use including NICE (National Institute for Care and 
Excellence) guidelines generally recommends to avoid using combination of ARBs with 
ACEis (9,19,53,85) 
Based on the criteria as aforementioned, selected studies had either any ACE 
inhibitor versus any kind of CCB being the first line monotherapy OR the ones has any 
ARBs versus any CCB as the monotherapy being prescribed for hypertensive patients with 
all stages of kidney disease except Stage V (eGFR≥15 ml/min/1.73 m2 or UAE <300 mg/d) 
and for patients with or with diabetes.  
In overall, I screened titles and abstracts for the studies based on this topic and 
retrieved all the articles that can potentially meet inclusion criteria based on Population, 
Intervention, Comparator and outcomes as well as methodology the studies have employed. 
In terms of study design, I had searched for all kinds of study designs including 
experimental as well as non-experimental studies such as cohort and case control. 
Apart from all that, the Study had an intention to include an independent reviewer 
for study selection. However, independent reviewer could not complete the task, given the 
tight schedule of the thesis completion. Nevertheless, Quality of our selected studies for 
this Systematic review and Meta-Analysis were independently assessed by another 
separate reviewer. There were no disagreements with reviewer. 
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3.4. Study outcomes 
The three main outcomes of this study are RR for proportion with further 
progressed CKD and WMD for changes in BP measurements including SBP as well as 
DBP. All the outcome values were expressed in terms of Mean ±SD unless it is stated as 
median with 25th and 75th percentiles.  
3.4.1. Primary Outcome 
The primary outcome of this study is further progression of CKD in terms of added 
decline in GFR values or by further increase in UAE levels than at the baseline. I chose 
these two measures as they were more reliable measures based on NIDDK (43). Estimated 
GFR levels is a measure that will be calculated based on blood creatinine test, age, gender 
and body size according to National Kidney Foundation (86). It can be calculated based on 
Plasma clearance and cystatin C as well (86). It was expressed in ml/min/1.73m2. Studies 
with estimated GFR are based on any of the existing equation with components such as 
iothalamate clearance, inulin, Cr-EDTA, Tc-DTPA, or iohexel, were included as part of 
this study because GFR equation according to KDOQI guidelines is relatively new and 
most of the studies that met the study criteria were done earlier than 2015. Based on eGFR, 
a person is said to be normal level of having eGFR when one is having eGFR of more than 
90 ml/min/1.73 m2, he/she is considered to be in Stage I, 90-60 ml/min/1.73m3 being 
considered as CKD Stage II and lower than 60 ml/min/1.73 m2 is the stage III CKD at 
which it is considered to have actual impairment in the renal function and lower than 15 
ml/min/1.73 m2 are suspected to have developed kidney failure (43).  
In regards to UAE as an alternative measure of outcome, same condition was applied 
as there is no one unified way of determining it. I accepted all the studies with any of the 
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immunochemical methods for ascertaining UAE levels such as immuno-nephelometry, 
radioimmunoassay and immuno-turbidimetry (87). 
Based on these aforementioned measures for CKD, I was interested in estimating the 
overall pooled RR for the proportion with progressed CKD that was based on further 
decline in GFR/increase in UAE levels. 
 3.4.2. Secondary Outcomes 
BP control is the secondary endpoint of this study, which was calculated based on 
change in SBP as well as DBP by the end of the study duration in relation to the BP at the 
baseline. Any device that assess BP were included for this study without any restriction 
such as Hawksley random zero sphygmomanometer, mercury sphygmomanometer 
(Korotkoff I and V), or using any certified equipment (Spacelabs 90207, Redmond, WA, 
USA) like mentioned in of the included studies. This is because comparative studies done 
on devices used for assessing BP, indicated that they were all more or less same with each 
other (88). BP measurements taken in any position including sitting, supine and standing, 
were considered as a part of this study. 
Concerning BP outcomes, it included (a) mean SBP change and (b) mean DBP 
change, which were both ascertained in the form of WMD during quantitative analysis. For 
both the secondary outcomes including WMD in SBP and WMD DBP, I estimated mean 
differences to calculate WMD based on the differences observed at the end of follow up in 
relation to the observed value at the baseline (89).  
In other words, formula was as following: 
  Mean differences = Baseline mean – Final mean or the mean at the end of Follow up 
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Apart from aforementioned study outcomes, I had an intention to look at additional 
CKD outcomes such as mean change in GFR rates as well as mean differences in UAE 
levels, and additional BP outcome such as the proportion with controlled BP. However, 
there were no sufficient data in regards to those additional CKD outcomes as only two 
studies reported required data and BP outcome from neither of the included studies. Due 
to these issues, I dropped the idea of doing meta-analysis on these additional BP and CKD 
outcomes. 
3.5. Data Extraction 
Data extraction from selected studies has been confirmed independently by another 
reviewer. It includes a section with baseline characterstics such as mean age, gender, race, 
origin of the study, history of Heart diseases as either Yes or No, type and dosage of ARBs, 
ACE inhibitors and CCBs; duration of therapy, co-interventions such as concurrent use of 
sodium restriction or diuretics, doses given, primary as well as secondary outcomes of the 
included studies and summary of each study findings given in following section with 
measurements of SBP and DBP levels in mmHg, and eGFR in ml/min/1.73 m2 or urinary 
albumin excretion levels at baseline and follow-up,  
In regard to mean age based on all the selected studies, I calculated manually based 
on the mean age of each study. In other words, mean age of the included studies was the 
average taken from the sum of averages of each study.  
Apart from all that, there was a study that had only median and Interquartile range 
instead of Mean and Standard deviation (SD), I contacted authors in this case for the mean 
and SD of BP measurements, GFR values or UAE levels. However, one of the two authors 
responded that they do not wish to provide the data. Another study had not reported 
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aggregate mean and SD but across subgroups such as race and gender in which case I had 
contacted Author for providing us with aggregate mean for which I did not receive any 
response.  
When comparison of studies are made and doses are varying, the studies with 
highest dose are usually considered (90). However, I had included all doses to examine if 
it has differential impact on the outcomes. Moreover, I also chose studies with add on 
therapies as per our inclusion criteria. I also examined if intention to treat analysis was 
done for those with high loss to follow-up in relation to the number of events occurred. 
As for our quantitative analysis, I determined overall pooled estimates for all three 
outcomes including CKD and BP outcomes using meta-analysis such as (i) Relative risk 
for CKD progression, as our primary outcome, and (ii) Weighted mean differences (WMD) 
in SBP and (iii) Weighted mean differences in DBP as our secondary outcomes. With 
regard to Meta-analysis for CKD outcome, which is to determine RR, I retrieved the data 
such as number of total participants, cases, and non-cases for each group. In regards to our 
meta-analysis that were done for secondary BP outcomes, which are to determine (i) WMD 
in  SBP, and (ii) WMD in DBP change separately, I extracted the data regarding sample 
size, mean differences from baseline by the end of follow-up (FU), and its respective 
standard deviation (SD) for both the treatment groups. 
As a matter of the fact, none of the studies had reported Standard deviation 
explicitly, for mean differences for both the intervention arms. However, I had managed to 
calculate the standard deviation manually using the given standard deviation for baseline 
as well as for the end of follow-up and the sample size (n). The formula of SD for mean 
differences that was used in this study was following: 
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SD = √(SE at the baseline)2+ (SE at the end of follow-up)2 
Where, SE = SD of baseline or end of follow-up divided by √n 
This formula was used to calculate the SD for mean differences in both the groups 
–RAS as well as CCB. It is important to note that I had an assumption for this study 
regarding the SD. I assumed that the SD at the baseline were to remain same until the end 
of FU in an ideal situation (89). So, whichever study that did not report SD at the end of 
follow-up, I used the SD at baseline for the end of FU as well. Concomitantly, I do 
acknowledge that the precise SD at the end of the follow-up must have been different due 
to sampling error for those studies that did not report them. However, I made an assumption 
to enable inclusion of those studies by considering them as an ideal case. 
3.6. Quality Assessment 
 In this study, risk of bias assessment for methodological quality was done 
using Cochrane Collaboration tool (91). It is based on seven items such as random sequence 
generation, allocation sequence concealment, blinding of participants and personnel, 
blinding of outcome assessment, incomplete outcome data, selective outcome reporting 
and other biases such as funding bias if manufacturer of medication is the source of fund 
for the study trial (91). These domains cover various prominent biases such as selection 
biases, performance bias, attrition bias and detection bias. For instance, first two domains 
affects selection bias as without randomization, individuals might be selected selectively 
for each of the interventions. In addition, without allocation concealment, individuals can 
know which medication they are assigned to and potentially tried to change if it is not of 
their choice, which can create bias. In terms of other biases, it can include funding or any 
other bias that are not covered in other domains (91,92).  
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Biases under each of those eight domains can be judged as either low, high or 
unclear. If information is sufficient, I have reported it as low, unclear in case of lack of 
details reported and high risk if the method adopted was unsatisfactory or insufficient that 
has high likelihood to alter the results. These justifications for judgements as any of these 
options, are based on Chapter 8 of the Cochrane handbook (91,93).  
Any discrepancies in the assessment with independent reviewer were resolved 
without conflicts. Cochrane collaboration tool was executed with the help of RevMan 5.3 
to produce Risk of bias plot and summary graph based on the studies selected as a part of 
this review. 
3.7. Data Synthesis and Analysis  
This study primarily began with exploring baseline characteristics and summary of 
findings of the included studies followed by the detailed description tables for each single 
study, which was provided in the Appendix B.  
With regard to quantitative analysis, I used MetaXL software v5.3 to determine 
overall pooled estimate of RR for primary CKD outcome and WMD for secondary BP 
outcomes using IVhet (Inverse variance heterogeneity) model. I preferred IVhet to other 
models because it has been considered as optimal for the meta-analysis with few numbers 
of studies and high heterogeneity (83,94).  Furthermore, it is proven to be better than 
Random effects model and that it covers issues concerning underestimation of standard 
error, CI’s poor coverage and elevated MSE (83,94–96). However, I had executed Fixed 
effects and Random effects model as well for CKD outcome for exploratory purpose (95). 
In regard to BP outcome, quantitative analysis was done based on 4 studies that reported 
mean values at the baseline and end of follow-up along with SD to produce weighted mean 
   
     
24 
 
differences (WMD) using IVhet model, for which each study will be weighted by its 
sample size (97,98). As for publication bias, I assessed Doi plot that measures the bias 
based on LFK (Luis Furuya Kanamori) Index that will provide us with a value that can 
show the indication for bias (95,99). If the value less than -1 and 1, it is considered as “no 
asymmetry” which states that there is no publication bias. In addition, when the values are 
between |1| and |2|, it shows there is “minor asymmetry”. Moreover, if the LFK index goes 
beyond |2|, it is said to be having “major asymmetry”. The advantage of this plot is that it 
is more sensitive than funnel plot and was proven to be well suited for meta-analysis with 
fewer than 10 studies unlike Funnel plot (99). Hence, I preferred Doi plot over funnel plot 
(95,99,100). For those Meta-analyses with more than 25% heterogeneity, I wanted to do 
sub-group analysis or Meta-regression to identify source of variation in effects across 
various subgroups. However, I could not do further heterogeneity assessment as there were 
only very few meta-analyzable studies with which quantitative synthesis were done (101). 
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guides 
reporting of this study and its checklist has been enclosed as Appendix C (102,103).   
3.8. Ethical considerations 
This study did not require any primary or secondary data collected from individual 
or group of patients’ data that would demand confidentiality, privacy and protection since 
it was a systematic review and meta-analysis based on published experimental studies from 
the literature. However, a QU IRB approval was sought, and it was approved with an 
exemption. 
3.9. Funding source 
This project was not funded by any source. 
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CHAPTER –4:  RESULTS 
4.1. Results of the search 
As for producing this review, the search was seemingly comprehensive with results 
based on multiple databases and by hand search of all potential and included studies. 
Overall, the search that included a time window up to September 2019 resulted in 5826 
citations. Out of which, 4579 citations were retrieved from three major databases with 
1090, 1799, and 1720 being identified through PubMed, Embase and Cochrane Library 
respectively. In addition to that, 1247 of additional search results were being identified 
through other sources including reference lists, Clinical Registry of Unpublished trials, 
WHO, Scopus and ProQuest. Majority of the results were by hand search and only less 
than 10% of it constituted the results from the other sources. After reading titles, 2689 
duplicated were identified and thereby removed which then resulted in total of 1569 records 
that met the criteria by title and majority of them comprising of 1462 results were then 
excluded after reading Abstracts.  
A total number of 107 were, consequently selected for full text articles assessed for 
Eligibility. However, 100 results were excluded due to several reasons such as outcomes 
of interest not reported either BP or CKD outcome(n= 67) as the study must include both 
of its main outcomes, insufficient duration of study (n= 21), wrong add-on therapy/ 
crossover (n = 9) and studies that used same population (n=3).   
Besides, since its systematic review, I tried hand searching the reference lists and 
all the databases as mentioned earlier except Embase for observational studies as well. 
However, there were no non-experimental studies in the context of my topic that met my 
study criteria. I eventually had only seven studies that met our inclusion criteria for our 
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qualitative synthesis. However, not every study had required values to estimate the pooled 
effect sizes such as cases and controls from each arm due to which our Meta-Analysis was 
done on 3 studies only for CKD outcome. Correspondingly, only 4 studies were suitable 
for meta-analysis for secondary outcome. The study flow diagram based on the PRISMA 
checklist was shown in Figure 1. 
 
Figure 1: Study flow diagram 
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4.2. Characteristics of Included studies  
Baseline characteristics of the included studies were shown in table 2. I identified 
seven randomized controlled trials that met our inclusion criteria. Despite of a search 
without restriction to experimental studies alone, only RCTs were found to meet the criteria 
of this study. That is the reason why study has been entitled as “Systematic review and 
meta-analysis of RCTs”, even though search was not restricted to RCTs alone.. All of them 
comprised of direct head-to-head comparison with RAS inhibitors either ACEi or ARB 
compared against CCB.  Out of seven included trials (n=24446), four of them (57.1%) were 
based on ACEi compared with CCB with 19663 participants (38–41). Rest of the three 
trials constituting 42.8% were done based on comparison between ARB and CCB with a 
total of 4783 participants (42,80,104). Trials that did a comparison with placebo were not 
identified for this study. 
4.2.1. Age: 
Based on the table 2, the mean age of participants across all the included trials was 
56.6 years. Most of the trials had an age range  between 50 and70 years (38–42). 
Nonetheless, two of the included trials were limited to an average age of patients less than 
50 years (80,82). Mean age of population in trials that had a direct comparison between 
ACEi and CCB was 59.12 years with a range of 50-70. On the other hand, the average age 
of patients in trials that investigated ARB versus CCB was 53.3 years with a range of 45-
65.  
4.2.2. Country or the origin of the study: 
Two of the trials recruited participants from USA with 19196 participants 
constituting 78.5% of total participants (38,41). One of the remaining trials was from Turkey 
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with 20 participants (<1%) (82); another one from Japan with 4703 participants (19.2%) 
(42). Rest of them (42.8%) were found to recruit from European countries such as Sweden, 
Italy, and Greece with a total of 527 participants accounting for 2% (39,40,80).  
4.2.3. Male proportion: 
 As for the gender of the participants, three of the studies (42.8%) had reported 
around 50-55% of male population in their study (40–42). While three other studies 
(42.8%) reported around 60-65% of men in their trial (38,39,80). Nevertheless, the smallest 
of all included trial, had not reported the gender proportion (82).  
Furthermore, HTN can be said as either primary or secondary, wherein primary is 
the one with HTN due to non-identifiable cause while secondary is the one with several 
secondary causes (105,106). In this study, patients in all the trials were considered to have 
eGFR >15 ml/min per 1.732 or urinary albumin excretion levels <300mg/24h. In other 
words, included trials comprised of patients without CKD (82) or with CKD of any stage 
from 1-4 but with exception of stage 5 (38–42,80), which represents Kidney failure or need 
for kidney transplantation or dialysis. Hence, this study assessed alternative therapies used 
in treating patients with primary as well as secondary causes of HTN as it includes people 
with or without CKD, with or without diabetes and patients with low and high-risk 
hypertension.  
4.2.4. Length of the follow-up: 
Study duration of all the included trials was of 3 months at minimum. Trial by Ay 
et al (2013) was the one with smallest duration and trial by Leneen et al (2006) had the 
highest length of the follow-up with 4.9 years. 
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Table 2: Characteristics of included studies 
Author Year  Country  P  I  LoFU 
History 
of Heart 
Diseases 
 
CoI Study endpoints 
Agodoa 
et al. 2001 USA 
Non-diabetic (100%) 
African Americans with 
mean age of 54.3 and 
GFR of 65-20 ml/min per 
1.732 (n=1094) 
CCB 
vs 
ACEi 
vs BB 
3 years 
 
 
 
NR 
 
 
 
NR 
Primary: Rate of change in GFR  
Secondary:Composite Index of 
the clinical endpoints of 
reduction in GFR of more than 
50% or 25ml/min per 1.73m2 
Herlitz 
et al. 2001 Sweden 
Non diabetic patients 
(100%) with 
uncontrolled HTN with 
mean age of 53 years and 
GFR >20 ml/min/ 1.73 
m3 (n=158) 
CCB 
vs 
ACEi 
vs 
CCB+
ACEi 
1.73 
years*
* 
NR NR Change in BP measurements and renal function  
Fogari et 
al. 2002 Italy 
Diabetic outpatients with 
mean age of 62.5 years 
and microalbuminuria 
(n=309) 
CCB 
vs 
ACEi 
vs 
CCB+
ACEi  
4 years  NR NR 
Primary: Effect on 
Microalbuminuria,  
Secondary: cardiovascular 
outcomes 
Leneen 
et al. 2006 USA 
Diabetic participants 
(41.2%) with mean age 
of  66.7 years (n=18102) 
CCB 
vs 
ACEi 
4.9 
years Y Y 
Primary: Composite of fatal CHD 
or non-fatal MI 
Secondary: All-cause mortality, 
fatal and non-fatal stroke, 
combined CHD, combined CVD. 
Other pre-specified secondary 
outcomes such as end-stage renal 
disease [ESRD], cancer, 
hospitalization for GI bleeding, 
angioedema, and ECG-left 
ventricular hypertrophy (LVH) 
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Author Year Country P I LoFU 
History 
of Heart 
Diseases
 
CoI Study endpoints 
Ogihara 
et al. 2008 Japan 
Hypertensive diabetic 
Japanese patients 
(42.9%) with mean age 
of 63.8 years (n=4703) 
ARB 
vs 
CCB 
3.2 
years*
* 
Y Y 
Primary: Sudden death, 
Cerebrovascular, cardiac, renal 
and vascular events 
Secondary: All-cause deaths, 
new-onset diabetes and 
discontinuance of treatment due 
to adverse events 
Liakos 
et al. 2012 Greece 
Non diabetic Caucasian 
hypertensive patients 
with mean age of 46.9 
(n=60) 
ARB 
vs 
CCB 
9 
months NR NR 
Effect on acute exercise induced 
inflammatory and thrombotic 
response  
Ay et al. 2013 Turkey 
Non diabetic patients 
with mean age of 49.4 
years (n=20) 
ARB 
vs 
CCB  
3 
months NR NR Effect on Microalbuminuria  
*ACEi – Angiotensin converting enzyme inhibitor; CCB – Calcium channel blocker; CVD – Cardiovascular Disease; UAE – 
Urinary Albumin excretion; CHD – Coronary Heart Disease; HF- heart failure; ARB – Angiotensin receptor blockers; MI – 
Myocardial Infarction; RRR – Relative risk reduction; P-Population; I-Interventions in the study; NR-Not reported; LoFU-Length 
of the Follow-up; CoI- Cointervention such as concomitant use of sodium restriction/diuretics/beta blockers; Y indicates YES, and 
N indicates NO; 
**LoFU expressed in terms of mean  
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4.2.5. Race/ ethnicity of the population: 
In terms of ethnicity, one of the studies was based on African Americans in which 
study focused on Blacks alone (38). While another study comprised of blacks as well as 
non-blacks (41). Two of the other studies (28.5%) reported that their study were based on 
Japanese and Caucasian patients only, respectively (42,80). Three trials constituting almost 
43% had not reported ethnicity of their participants in their respective studies (39,40,82).  
All trials had sought informed consent from their participants prior to their trial 
initiation. I had included all the participants with any stage of hypertension, any stage of 
CKD except Stage 5, which is in state of kidney failure seeking transplantation or dialysis. 
I also included those studies for which patients had diabetes as well as non-diabetes to 
compile the evidence on Hypertensive patients progressing to further decline in GFR or 
rise in Albumin levels regardless of the history of any CVD events. Trials that were already 
taking RAS inhibitors or CCBs were not included as it would over or underestimate the 
effect of medication if any effect is actually present. Also, trials with crossover design was 
excluded to avoid biased estimate; however, any add on therapy other RAS inhibitors for 
CCBs and any add on therapy for either of the RAS inhibitors other than CCBs were 
included in this review.  
4.2.6. Diabetic status of the population group: 
Majority of the trials were of non-diabetic participants (38,39,80,82). Participants 
in three of the trials (42.8%) were comprising of high-risk hypertensive patients due to 
which they had reported prevalence of diabetes at baseline and specifically controlled by 
diet, or by medication of metformin or its combination with sulfonylurea in case of study 
by Fogari et al (2002) (40–42).  
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4.2.7. Co-interventions: 
Concomitant use of sodium restriction or diuretics has the potential to confound the 
true effect of the study based on the existing literature (107,108) As shown in table, none 
of the included trials reported either of co-interventions except for two studies that showed 
use of diuretics simultaneously (41,42).  
4.2.8. Endpoints of the included studies: 
 Primary outcome of most of the trials (57.1%) were renal outcome based, including 
decline in eGFR ml/min per 1.73m2 and change in urinary excretion levels (mg/d) 
(38,40,42,80). One of the trials (14.1%) did not specify renal outcome neither as primary 
nor secondary (80). Another one included trial had end-stage renal disease as secondary 
outcome (41). The studies with high risk hypertensive patients with diabetes and history of 
Cerebrovascular, cardiac and/or vascular related events at baseline had different heart 
events including stroke, heart failure, angina, CVD, CHD as either primary or secondary 
outcome (40–42). Moreover, two of those three trials (66.6%) with high hypertensive 
patients, all cause mortality or sudden death events were mentioned as secondary outcome 
(41,42).  
4.2.9. Interventions in the included studies: 
Only four (57.1%) of the included trials considered interventions as monotherapies 
such as any of RAS blockers vs any of CCBs (41,42,80,82). On the contrary, rest of the 
three trials (42.8%) had three arms in the study such as a combination therapy of the 
respective RAS inhibitor with that specific CCB in addition to two arms of monotherapies 
(38–40). 
4.2.10. Doses of the medications: 
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Based on Appendix B, it is very apparent that doses of study drugs across studies 
are quite varying ranging from 2.5mg/d to 300 mg/d. However, in trials that compared 
ACEi vs CCB, it was worth noting that regardless of dose variation, GFR decline is found 
to be higher in ACEi compared to CCB (38,39,41). In terms of UAE as well, ACEi dropped 
better than CCB (40).  
In case of trials that compared ARBs with CCBs, ARB and CCB seemed to show 
quite similar GFR throughout the study duration (80). As for renal events based on 
proteinuria or Albuminuria, there were no significant difference with no regard to varying 
doses (42). Nonetheless, one of the trials (14.1%) showed that CCB has higher level of 
decrease in UAE levels than ARB (82). Apart from that, three out of trials in this review 
were seen to have been given with add on therapies when BP goal was not achieved 
(38,41,80). Moreover, One trial indicated that it increased its doses whenever needed or 
target was not met for BP (42).  
In one of the trials (14.1%), even though medications were randomly assigned, 
before analysis of the study, 9.3% and 48.7% from ARB and CCB arms respectively were 
withdrawn due to either loss of interest, pregnancy, side effects, non-compliance or adverse 
events such as coronary artery disease. Intention to treat analysis was not done due to which 
analysis was done on the remaining participants who were verified for inclusion based on 
study criteria. 
Two of the included trials seemingly had washout period of 2-4 weeks prior to 
treatment assignment (39,40). Reasons for withdrawal were reported in two of seven trials 
constituting 28.5% of the trials (39,40,80). Additionally, two of the trials indicated the 
adverse events in their study (39,40).  
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4.3. Risk of bias assessment  
In this study, all of the included studies were based on randomized controlled trials, 
which were selected for this review after assessing its eligibility criteria. Risk of bias 
assessment were presented in Figure 2 and 3. Most of the studies (71.4%) reported that it 
was randomized, computer generated or with a code in which case, risk was assessed as 
low (38–42). While for those trials with no details (28.5%), it has been reported as unclear 
(80,82).   
Two (28.5%) of the trials mentioned that they were open label which can introduce 
bias (40,42). One of the trials (14.1%) mentioned that study medications were supplied by 
manufacturer but reported that were not involved in any part of the study such as design 
and conduct, collection, analysis and interpretation due to which other bias was reported 
as unclear as I are not certain if they had interfered (41).  
Another trial (14.1%) had clearly reported that pharmaceuticals granted them 
unrestricted funding for which I reported other bias as high because funding bias is likely 
in that case (42). Three of the trials (42.8%) that had loss to follow-up greater than 20% 
was reported as high risk (39,40,80).  
Based on these above given figures, two studies were considered to be with low 
risk of bias (38,41). While two studies seemed to have high risk of bias (40,42). One of the 
studies were apparently having unclear risk of bias (82). Rest of the studies seemed to have 
moderate risk of bias (39,80). 
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Figure 2: Risk of bias graph: review authors' judgements about each risk of bias item 
presented as percentages across all included studies. 
 
Figure 3: Risk of bias summary: review authors' judgements about each risk of bias item 
for each included study 
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4.4. Main Study Outcomes: 
 Table 6 shows Summary of findings based on all the included studies. There were 
three trials with no diabetes and CKD stage 3 (38,39,82) and a trial with no diabetes but 
CKD stage 1 (80). Two trials with diabetes as well as CKD stage 3 (40,42) and a trial with 
diabetes as well as CKD stage 2 (41). Out of seven, three trials reported CKD outcome 
measures in terms of UAE levels (40,42,82).  Rest of the trials measured CKD in terms of 
GFR (38,39,41,80).  
4.4.1. CKD  
4.4.1.1. Narrative: 
In terms of CKD outcomes as shown in Table 6, only one trial (14.2%) measured 
eGFR and it had similar reduction in both the arms (80). As for the other two trials (28.5%)  
that were reported in terms of UAE levels, one study showed greater reduction in UAE for 
CCB than ARB arm while the other remaining trial showed that UAE levels reduction was 
somewhat similar in both the regimens. only one of four trials were mentioned in UAE 
levels for which there was decrease but reduction in ACEi was slightly higher than CCB 
(40). On the other hand, for the trials with GFR, there was a decline in both groups but the 
decrease was greater in ACEi compared to CCB in one trial, and another one showed higher 
reduction in CCB than ACEI in the long term (38,41). In case of study by Agodoa et al 
(2001), they reported that in the short term, the decrease in GFR was higher in CCB than 
ACEi (38). 
4.4.1.2. Overall Relative Risk for CKD progression: 
There were only 3 studies that were meta-analyzable as the other included studies 
did not provide the number of participants that were reported to further progress in terms 
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of CKD. Each study showed different level of incidence of CKD progression amongst 
those who used RAS vs. those who had CCB. The total number of participants from both 
the arms were 23458, out of which cases were found to be 382 constituting 1.62% of 
participants having progressed to further CKD from both the treatment groups as shown in 
table 3. 
Table 3: Input table for pooled RR for CKD progression 
Study name RAS CCB 
N1 Cases Non-cases N2 Cases 
Non-
cases 
Agodoa et al, 2001 436 70 366 217 43 174 
Leneen et al, 2006 9054 126 8928 9048 129 8919 
Ogihara et al, 2008 2354 4 2350 2349 10 2339 
Total 11844 200 11644 11614 182 11432 
 
With the help of MetaXL software as mentioned in the Methods section, I yielded 
forest plots for overall RR using IVhet model in addition to conventional models such as 
fixed and random. Based on Figure 4 that has shown the IVhet model, overall pooled 
estimate of RR for CKD progression was found to be 0.90 [95% CI of 0.69, 1.16]. This 
means that pooled estimate favours RAS (Intervention) over CCB (Control). Thereby, 
forest plot shown in Figure 4  has indicated that there is 10% lower risk for further CKD 
progression for those with RAS compared to those with CCB. In to regard to 95% CI, I are 
95% confident that RR lies between 0.69 and 1.16, but it was not presented to be 
statistically significant as the interval contained null value of 1.  
Based on forest plots for Fixed effects as shown in Figure 5, pooled estimate of RR 
was shown to be 0.90 [95% CI of 0.74, 1.09]. This RR was same as that of IVhet model 
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and interpreted that there was seemingly 10% lesser risk for further progressed CKD 
amongst those who have taken RAS blockers compared to those with CCB. The 
heterogeneity was seen as low with I2= 25% and was not significant as they reported p 
value as 0.26 which was greater than 0.05, indicating a fair amount of consistency between 
studies. Also, this is evident from overlapping of confidence intervals for individual study 
point estimates, which again confirms that there is no statistically significant difference 
between studies. In addition, when I executed Random effects model as shown in Figure, 
the pooled estimate was similar to other two models mentioned above, with RR of 0.87 
[95% CI of 0.68, 1.13]. This means there was 13% lower risk for progressed CKD for those 
with RAS drug compared to CCB users. However, both the pooled risk ratios are not 
statistically significant as their CI contains 1. 
 
Figure 4: Relative risk estimate for CKD progression using IVhet Model 
CKD Progression IVhet
RR
1
Study 
Ogihara et al, 2008  
Agodoa et al, 2001  
Overall 
Q=2.68, p=0.26, I2=25%
Leneen et al, 2006  
    RR (95% CI)          % Weight
   0.40  (  0.13,  1.27)      2.9
   0.81  (  0.57,  1.14)     32.6
   0.90  (  0.69,  1.16)    100.0
   0.98  (  0.76,  1.25)     64.6
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Figure 5: Relative risk estimate for CKD progression using Fixed Effects Model 
 
Figure 6: Relative risk estimate for CKD progression using Random Effects Model 
CKD progression Fixed Effects
RR
1
Study 
Ogihara et al, 2008  
Agodoa et al, 2001  
Overall 
Q=2.68, p=0.26, I2=25%
Leneen et al, 2006  
    RR (95% CI)          % Weight
   0.40  (  0.13,  1.27)      2.9
   0.81  (  0.57,  1.14)     32.6
   0.90  (  0.74,  1.09)    100.0
   0.98  (  0.76,  1.25)     64.6
CKD Progression Random Effects
RR
1
Study 
Ogihara et al, 2008  
Agodoa et al, 2001  
Overall 
Q=2.68, p=0.26, I2=25%
Leneen et al, 2006  
    RR (95% CI)          % Weight
   0.40  (  0.13,  1.27)      4.7
   0.81  (  0.57,  1.14)     38.0
   0.87  (  0.68,  1.13)    100.0
   0.98  (  0.76,  1.25)     57.4
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4.4.1.3. Publication bias: 
As for detection of publication bias using IVhet model, I assessed Doi plot as well 
as funnel plot. I detected major asymmetry with LFK index of -4.84, which was farther 
away from 0, indicating the presence of publication bias, as shown in Figure 7. In other 
words, this plot indicates that study effects were not homogenous and that it was potentially 
affected by selection or other types of bias. 
In addition, I also estimated funnel plot as given in Figure 8 and it showed that all 
the studies were under the “funnel” indicating that there is no publication bias. Thus, it is 
not conclusive about bias as it was based on just three studies even though I believe that 
there is major bias as detected by Doi plot. 
 
Figure 7: Doi plot for detecting Publication bias for CKD progression using IVhet model 
CKD Progression IVhet
LFK index: -4.84 (Major asymmetry)
ln RR
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Figure 8: Funnel plot for publication bias for CKD progression using IVhet model 
4.4.2. BP control 
4.4.2.1. Narrative 
Based on the information presented in Table 6 given, it is understandable that in those 
three trials (42.8%) with ARB vs CCB, BP outcome was found to decrease but similar in 
both the regimens for two trials even though one of those trials consists of diabetic while 
other consist of non-diabetic participants with CKD stage 3 (42,82). However, the 
reduction is slightly higher in ARB than CCB for the remaining one trial (14.2%) and it 
comprises of non-diabetic but CKD stage 1 patients (80).  
 Meanwhile, for the rest of the four trials (57.1%) that had made a head to head 
comparison between ACEi and CCB, reduction in the BP level was similar in three trials, 
CKD Progression IVhet
ln RR
10-1
Sta
nd
ard
 er
ror
0.65
0.6
0.55
0.5
0.45
0.4
0.35
0.3
0.25
0.2
0.15
   
     
42 
 
of which two of them are with non-diabetic participants (38–40). However, all of those 
three trials (42.8%) had CKD stage 3. In case of the remaining one trial (14.2) with ACEi 
vs CCB comparison, BP decrease was higher in CCB than in ACEi arm (41).  
Based on the trials that reported mean SBP and DBP values at the baseline and end 
of follow-up, I executed a meta-analysis with 4 studies with total participants of 1538, out 
of which 874 (56.8%)  in RAS and 664 (43.2%) in CCB arm as shown in Table 4 and 5. I 
produced forest plots for mean differences in SBP as well as DBP using IVhet model from 
MetaXL software as mentioned earlier.  
Table 4: Input table for pooled estimate for Mean SBP change 
Study name RAS CCB N1 Mean diff StDev N2 Mean diff StDev 
Agodoa et al, 2001 417 16.5 1.595 209 17.1 2.452 
Fogari et al, 2004 102 17.2 1.671 103 19.9 1.733 
Ogihara et al, 2008 306 26.4 0.862 321 28.8 0.847 
Liakos et al, 2012 39 26.3 2.504 21 16.9 1.867 
 
Table 5: Input table for pooled estimate for Mean DBP change 
Study name RAS CCB N1 Mean diff StDev N2 Mean diff StDev 
Agodoa et al, 2001 417 13.8 0.993 209 14.3 1.366 
Fogari et al, 2004 102 11.8 0.864 103 12.8 0.878 
Ogihara et al, 2008 306 14.3 0.668 321 15.1 0.680 
Liakos et al, 2012 39 19.3 1.916 21 11.7 1.981 
 
4.4.2.2. Mean SBP change  
4.4.2.2.1. Overall WMD in SBP 
With WMD of -2.09 mmHg [95% CI of -5.96, 1.79], the forest plot apparently 
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favours the RAS (Intervention) over CCB (Control) for achieving a better reduction in 
mean SBP change. Since the summarized estimate had crossed a line of no effect, WMD 
of -2.09 mmHg is not statistically significant with CI containing 0.  
Based on qualitative visual analysis for the results of the studies, there seemed to 
be between-study heterogeneity. In addition, WMD for each study were found to be away 
from each other, appearing to be scattered on forest plot and were not lined up on a vertical 
axis, indicating a variability in the WMD among studies. In addition, there was no 
overlapping of confidence intervals in overall, which indicates that there is statistically 
significant differences between individual study point estimates. All of these confirms that 
there is fair amount of heterogeneity in the results.  
Based on quantitative tests for heterogeneity, with I2 of 99%, high level of 
heterogeneity is apparent. Moreover, Q statistics of 494.75 with p value of 0.00, which is 
lesser than 0.05 again suggests the inconsistency that apparent across studies.  
 
Figure 9: Weighted mean differences for SBP using IVhet Model 
Mean SBP change IVhet
WMD
1086420-2-4-6
Study 
Fogari et al, 2004  
Ogihara et al, 2008  
Overall 
Q=494.75, p=0.00, I2=99%
Agodoa et al, 2001  
Liakos et al, 2012  
    WMD (95% CI)          % Weight
  -2.70  ( -3.17, -2.23)      6.7
  -2.40  ( -2.53, -2.27)     81.3
  -2.09  ( -5.96,  1.79)    100.0
  -0.60  ( -0.97, -0.23)     10.9
   9.40  (  8.28, 10.52)      1.2
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 4.4.2.2.2. Publication bias  
As per LFK index of 4.32 from Doi plot as shown in Figure 10, it is important to 
understand that the major asymmetry and skewed to right; thereby denoting the possibility 
of publication bias as it is beyond 0. While on the other hand, Figure 11 of funnel plot 
indicated the likelihood for the publication bias in the study results as studies are slightly 
away the funnel. 
 
Figure 10: Doi plot for publication bias in Mean differences in SBP 
 
Figure 11: Funnel plot for publication bias in Mean differences in SBP 
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4.4.2.3. Mean DBP Change 
4.4.2.3.1. Overall WMD in DBP: 
With WMD of -0.71 mmHg [95% CI of -2.16, 0.73], the forest plot apparently 
favoured the RAS (Intervention) over CCB (Control) for achieving a better reduction in 
mean DBP change. Since the summarized estimate had crossed a line of no effect, WMD 
of -0.71 mmHg was not statistically significant with CI containing 0.  
Based on qualitative visual analysis for the results of the studies, there seemed to 
be between-study heterogeneity as studies were there on both the sides of scale. In other 
words, WMD for each study were found to be away from each other, appearing to be 
scattered on forest plot and were not lined up on a vertical axis, indicating a variability in 
the WMD among studies. In addition, there was not many overlapping of confidence 
intervals in overall, which indicates that there was statistically significant differences 
between individual study point estimates. All of these confirms that there is fair amount of 
heterogeneity in the results.  
Based on quantitative tests for heterogeneity, with I2 of 99%, there is high level of 
heterogeneity. Moreover, Q statistics of 258.06 with p value of 0.00 which is lesser than 
0.05 again suggests the inconsistency that apparent across studies.  
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Figure 12: Weighted mean differences for DBP using IVhet Model 
4.4.2.3.2. Publication bias  
With regard to Doi plot as shown in Figure 13, there was major asymmetry seen 
with LFK index of 4.11, which implied that there is publication bias as it is farther away 
from 0 and skewed to right. Meanwhile, Figure 14 shows funnel plot, and it denoted the 
likelihood for no publication bias in the study results as studies are fitted on the funnel with 
all the studies being scattered on the top of the inverted funnel. However, it is proven that 
Doi plots are better off with fewer than 10 studies due to which I conclude that there is 
possibly publication bias. 
Mean DBP change IVhet
WMD
86420-2
Study 
Fogari et al, 2004  
Ogihara et al, 2008  
Overall 
Q=258.06, p=0.00, I2=99%
Agodoa et al, 2001  
Liakos et al, 2012  
    WMD (95% CI)          % Weight
  -1.00  ( -1.24, -0.76)     13.4
  -0.80  ( -0.91, -0.69)     68.4
  -0.71  ( -2.16,  0.73)    100.0
  -0.50  ( -0.71, -0.29)     17.6
   7.60  (  6.56,  8.64)      0.7
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Figure 13: Doi plot for publication bias in Mean differences in DBP 
 
Figure 14: Funnel plot for publication bias in Mean differences in DBP
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Table 6: Summary Findings of Included Studies 
Author, 
year 
Study 
medications Effect on BP (mean, SD) Effect on CKD (eGFR/UAE level(s)) 
 
Agodoa 
et al, 
2001 
 
Ramirpil vs 
Amlodipine 
 
BP results, at the end of follow up were 
considerably lower than at baseline with no 
significant reduction across treatment groups 
(with p value >.10). In ramipril group, BP was 
151.0/96.0 mmHg at baseline and was 
decreased to 134.5/82.2 mmHg. Meanwhile in 
amlodipine group, it was 150.0/95.7 mmHg at 
baseline and was reduced to 132.9/81.4 
mmHg. 
 
Patients who were on Ramipril group was shown having 
mean decline in GFR of 1.15ml/min per 1.73m2 or 36% 
slower decline in GFR than amlodipine group with p value 
of 0.002 during chronic phase or over the study duration. 
Nonetheless, during acute phase or within the first 3 months 
of drugs assignment, It was seen that GFR increased by 
4.19ml/min per 1.73m2 more in amlodipine compared to 
Ramipril group with p value <0.001. However, the mean total 
slope which includes chronic as well as acute phase 
seemingly did not vary between both the groups with 
difference in total mean slopes=0.34 mL/min per 1.73 m2, 
95% CI,−0.41 to 1.08 and a p value of 0.38. Based on clinical 
end point analysis, unadjusted risk reduction for all the three 
endpoints such as GFR event, ESRD and death was 26% in 
Ramipril group when compared with amlodipine (95% CI of 
-4% to 47% with p value of 0.09). However, after adjusting 
for pre-specified covariates such as log transformed values 
of Urinary protein to creatinine ratios, history of heart 
disease, mean arterial pressure, age and sex, as per study’s 
analysis plan, it was shown that there was 38% RRR in 
Ramipril group compared to Amlodipine with 95% CI of 13-
56% and p value of 0.005 for ESRD and death, and with 95% 
CI of 10%-58% and p value of 0.01 for eGFR event as one 
of the clinical end points. 
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Author, 
year 
Study 
medications Effect on BP (mean, SD) Effect on CKD (eGFR/UAE level(s)) 
Herlitz et 
al, 2001 
Felodipine vs 
Ramipril 
Mean Change in BP over the study duration 
was -14.3/-15.0 mmHg and -13.5/-13.3 mmHg 
in Ramipril and felodipine groups respectively.
Study tried to differentiate between Acute effect on eGFR or 
1/serum creatinine levels which is based on overall effect 
calculated from baseline to first 3 months after 
randomization and longer term effects based on calculating 
regression coefficient from 3 months until the end of follow-
up. It was found that substantial acute reduction in eGFR was 
apparent in Ramipril group with  
-3.2±7.0 ml/min and a p value <0.01 but no significant 
difference was seen in Felodipine group with 0.4±8.0 
ml/min. It was also shown that with regard to longer term 
effects that was evident that Ramipril group (P value >0.20) 
had a slower progression rate in comparison to Felodipine 
group (p value <0.05) In monotherapy group OF Ramipril, 
mean ±sd of GFR was -2.1±10.0 vs -9.0±22 in amlodipine 
group. Adverse events amongst both the groups were similar.
Fogari et 
al, 2002 
Amlodipine 
vs Fosinopril  
BP changes were similar in both the groups 
with reduction being evident in the first 3 
months followed by persistence over the years. 
In fosinopril group, mean reduction was 
17.2/11.8 mm Hg while it was 19.9/12.8 mm 
Hg in Amlodipine group (with p value of 0.001 
vs placebo). 
Patients who were assigned to fosinopril therapy seemed to 
have significant decrease in UAE levels after only 3 months 
(Mean±SD of 98.2±67.3 to 63.8±38.4 mg/d with P value 
<0.01), and further slight decrease was observed in 6 and 12 
months of treatment and then remained to stay stable over the 
remaining study duration. On the contrary, Amlodipine 
seemed to take 18 months to show significant decrease in 
UAE levels (mean±SD of 95.51±64.1 to 70.9±41.2 mg/d 
with P value <0.01) which was lesser than what was observed 
in fosinopril treatment after first 3 months. In overall, by the 
end of the study, fosinopril (98.2 ±67.3 to 45.5 ± 25.2) shown 
greater reduction than amlodipine (95.5 ± 64.1 to 62.3 ± 33) 
in terms of UAE levels. 
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Author, 
year 
Study 
medications Effect on BP (mean, SD) Effect on CKD (eGFR/UAE level(s)) 
Leneen et 
al, 2006 
Amlodipine 
vs Lisinopril 
Mean BP at baseline was 146/84mmHg across 
both the treatment regimens. It was observed 
that during the follow up, BP was shown to 
decrease but BP higher on average by 
1.5/1.1mmHg in Lisinopril group than 
amlodipine. Based on BP assessed by race and 
gender, it was shown in both male and female 
non-blacks even though there was rapid 
decrease in treatment groups, Lisinopril arm 
was still kind of having higher BP when 
compared to amlodipine by 0.0/0.5 mmHg in 
men and 1.3/0.9mmHg in women. On the 
contrary, decrease in BP was somewhat lesser 
in blacks than in non-blacks and it was higher 
under Lisinopril arm vs amlodipine arm for 
mean follow-up BP difference of 3.9/2.1 
mmHg and 2.7/1.6 mmHg in black women and 
black men respectively. In case of two 
subgroups of age, non-diabetics and CHD 
patients at baseline, there was no major 
difference in BP between groups with only less 
than or equal 1 mmHg higher in Lisinopril arm. 
In diabetic patients, SBP was found to rise 
from 1.4 to 2.0 mmHg in the ACEi arm. 
In overall, eGFR was shown to decrease in both the groups; 
however, the decrease in Lisinopril arm (77.7 to 70.7 ml/min 
per 1.73m2) was higher than in amlodipine arm (78.1 to 75.1 
ml/min per 1.73m2). In terms of Clinical outcomes, ESRD 
events were similar in both the arms with RR of 0.99 with CI 
of 0.77 -1.26 and a p value of 0.929. 
Ogihara 
et al, 
2008 
Candesartan 
vs 
Amlodipine 
In overall, BP was well controlled in CASE J 
trial with both the medications. In case of 
Candesartan group, mean BP was 162.5/91.6 
mmHg at baseline and was decreased to 
136.1/77.3 mmHg and in Amlodipine group, it 
At baseline, it was mentioned that around 24.3% in 
Candesartan group and 23% in Amlodipine group had history 
of renal events, which is presence of proteinuria and serum 
creatinine levels ≥1.3mg/Dl. In terms of renal events across 
both the groups, there was no statistically significant interval 
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was 163.2/91.8 at baseline and was reduced to 
134.4/76.7 mmHg. 
risk ratios across both the treatment regimens with CI 
containing 1 for HR. ESRD had HR of 0.40 with CI of 0.13- 
1.29 and a p value of 0.112. 
Liakos et 
al, 2012 
Irbesartan vs 
Diltiazem 
In overall, mean BP at baseline was 141.4/94.0 
mmHg and was under control at the end of 
follow up with 118.4/77.4 mmHg (with p value 
<0.001 vs baseline). In case of Irbesartan 
group, mean BP was 142.7/94.8 mmHg at 
baseline and was decreased to 1116.4/75.5 
mmHg. Meanwhile in diltiazem group, it was 
139.1/92.6 mmHg at baseline and was reduced 
to 122.2/80.9 mmHg. 
In overall, eGFR seemingly did not have any significant 
difference from both the groups, which were found to be 
similar in the baseline (111.1± 30.3) and at the end of follow-
up (110.4± 28.4).  
Ay et al, 
2013 
Valsartan vs 
Amlodipine 
BP had shown significant decrease post 
treatment in both the groups. At baseline, 
Mean SBP and DBP were 155.2± 8.3 and 94.5 
± 10.6 mmHg in the amlodipine group and 
156.5±12.6 and 92.7 ± 5.8 mmHg in the 
valsartan group. After treatment, mean SBP 
before and after treatment were 155.8± 10.4 
and 127.3± 5.9 mmHg respectively and mean 
DBP observed at baseline and at the end of 
follow-up were 93.6 ± 8.3 and 77.4± 6.4 
mmHg, respectively (with p value <0.001). 
Amlodipine group showed reduction in UAE levels from 
18.4±14.2 mg/d to 8.96 mg/d while valsartan group which 
had lower levels of UAE in the baseline with 9.2±5.2 was 
reduced to 8.91 mg/d. In other words, there wasreduction 
shown in both the groups but the decrease was higher in CCB 
group than ARB arm. 
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CHAPTER –5: DISCUSSION  
 
5.1. Summary of the main results  
After completion of a comprehensive and systematic search, and selection 
process as per the eligibility criteria that was set, tototal of seven trials for SR were included 
in the systematic review of this study.These trials comprised of 24446 participants in total 
and assessed two treatment strategies of interests - any RAS inhibitors vs any CCB amongst 
diabetic as well as non diabetics, and with either of CKD 1-4 stages (38–42,80,82).  . The 
two prominent outcomes of this review are changes in BP measurements and effect of those 
specific antihypertensive drugs on progression of CKD ranging from stage 1-4. These 
outcomes are vital from patients perspective for their understanding about their own health 
(22).   
As for quantitative analysis of CKD outcome, 3 trials with n= 11844 were 
included Based on the findings of this study, thereby states that there is no statistically 
significant difference based on pooled estimate of RR of 0.90 [95% CI 0.69, 1.16] using 
IVhet model for the proportion who progressed to further CKD as the summarized estimate 
has its CI containing null value. And in case of BP outcome, MA was based on 4 trials with 
n= 6166. In regard to BP outcomes, the mean difference in SBP as well as DBP were -2.09 
[95%  CI -5.96, 1.79] and -0.71 [95% CI -2.16, 0.73] respectively with its confidence 
interval containing 1. This is closely aligned with the existing literature regarding the study 
drugs as both of them were proven with renoprotective and BP lowering effects, even 
though RAS blockers are established as reno-protective antihypertensive agents based on 
NICE guidelines.  
With the help of medications, it can only aid in slowing down the progression of 
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CKD (20,22). As a consequence, this review looked at such empirical studies to 
comprehend the effect that these drugs has on the aforementioned endpoints of this study.  
This study indicated that there is always a fall in BP with any of the 
antihypertensive medications of study interest which is in line with the other studies that 
were previously done (20,22,109). In terms of comparison made with ARB vs CCB as well 
as in case of ACEi vs CCB, it was evident that the BP-level decreases across all the 
medications, which appeared to be similar in both groups, except in two trials (38–
40,42,82). These two trials were distinct in terms of its characteristics. One of them was 
with non-diabetic and CKD stage 1 participants assessing CCB vs ARB with only 60 
participants over study duration of 9 months, which showed that reduction in ARB is 
slightly higher than that in CCB.  
On the contrary, the other one consisted of diabetic with CKD stage 2 patients 
assessing CCB vs ACEi with 18102 participants over the study duration of 4.9 years, which 
found that reduction in CCB is quite higher than the ACEi arm (41,80). This shows that 
there could be some external validity issues in existence in case of the former one with 
small sample size within less than a year. However, the latter could be projecting true 
results as it had a very large sample size including blacks and non blacks, and diabetic and 
non-diabetic and was held for almost 5 years (41). In addition to that, it was worth noting 
that the latter was studied on high-risk hypertensive patients which means that it cannot be 
applied for all the patients affecting the external validity of the study, which is concerned 
with applicability of evidence to other settings (41,110,111). Although all the other five 
trials showed comparable BP decrease in both the treatment regimens, they are distinct and 
has variation between studies. Some of those trials had large sample size, low vs high-risk 
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hypertension, presence of diabetes or heart events, sociodemographic characteristics of the 
population including age and sex are all varying across those studies (38–40,42,82,110).  
Based on this study review, it was found that most of the studies with ARB vs 
CCB either had similar effect in both the arms or better decrease in UAE levels amongst 
CCB group when compared to ARB (42,80,82) which was later confirmed by quantitative 
analysis based on meta-analyzable studies.  
Undoubtedly, the trials showing effect was based on a one large trial with 4703 
participants while the other one was smallest of trials with only 20 participants (42,82). 
Also, one of them is based on diabetic and another one is based on non-diabetic participants 
with varying stages of CKD. This again confirms that despite of the results it shows, studies 
are not promising enough to conclude based on these findings (22,112). 
In this review, I also compared ACEi vs CCB, and  based on narrative summary, 
majority of the studies shown that patients with ACEi are more likely to progress to further 
CKD with higher decline in the eGFR. On long term basis, ACEi seems to have higher 
decline in GFR, while CCBs were found to have higher decline in the first three months or 
in the short run (38–41). These studies are with and without diabetic participants. However, 
meta-analysis showed that there was no statistically significant differences between both 
the treatment regimens. Nevertheless, since the meta-analysis was based on few number of 
studies, further research with more larger studies with large sample size are required for 
those with and without diabetes to confirm findings extracted from this review. 
Combination therapy in those trials either as ACEi plus CCB or ARB plus CCB 
although not of our interest, it was quite appealing to know that it has better effect in terms 
of outcomes of our interest. Nevertheless, previously done systematic review and meta-
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analysis on combination therapy seems to have conflicting results and has stated no 
additional benefit can be retrieved by using combination therapy for reno-protection 
(29,40,109,113).  
Based on narrative, most of the trials indicated that rate of progression is higher 
in RAS inhibitors when compared dihydropyridine such as felodipine and amlodipine, and 
non-dihydropyridine calcium channel antagonists such as diltiazem. This seemed to be not 
aligned with the findings of Meta-analysis which had reported RR 0.90 [95% CI of 0.69, 
1.16] indicating that risk for CKD progression is lower in RAS users, even though this was 
not statistically significant. However, since some trials had less than 100 participants and 
had a length of follow-up as less than a year, study demands more larger studies to be 
conducted over longer year in the context of these study medications as direct comparison 
to make more meaningful inferences. Also, not all the studies used the same unified way 
of measuring BP and CKD outcomes in terms of eGFR (with varying equations). This also 
emphasizes that need for more studies with unified measures for outcome is just as 
important as having larger studies for better judgement of findings.  
As for results of other SR and MA in relation to my study results, it was quite 
unmatching. A similar systematic review and meta-analysis based of 8 trials with n=25,647 
done on the Renoprotective effect of RAS vs CCB showed CCBs to be weaker in terms of 
renal protection compared to RAS but for CKD patients (35). Their findings on CKD 
related outcomes demonstrated that higher probability for ESRD was linked with CCB 
compared with RAS based therapy with OR of 1.25 [95% CI, 1.05,1.48]. In terms of BP 
outcomes, However, they added that reduction was similar in both treatment regimens. My 
study seems to have conflicting results with their study as they have indicated highly 
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statistically significant OR in CCB groups while our study remained to show no difference 
between the Intervention and the comparator. 
As for one of the recent meta-analysis based on 7 trials with n=403which is quite 
similar to this study that compares CCB vs ACEis shows no benefit over the other and 
didn’t incude both RAS, only ACEI was compared (37). Their CKD related findings were 
MD in UAE levels =1.91μg/min [95% CI: -10.3, 14.12] and MD in GFR=0.01 [95% CI: -
0.38 to 0.41]. Their BP related results showed MD in SBP=1.05 mmHg [95% CI: -0.97, 
3.08], MD in DBP= -0.34 mmHg [95% CI: -1.2, 0.51]. This study shows similar results as 
this study with no statistically significant difference in outcomes between intervention and 
the comparator. 
Another yet to be published meta-analysis based on 23 trials with n=1805, its 
abstract had shown superiority of RAS over CCB on improving UAE levels but not 
considered other CKD measures such as GFR (36). Their CKD based results were MD in 
UAE levels of -0.442 [95% CI -0.660, -0.225]. Their study was done on diabetic CKD 
patients and their results were apparently statistically significant. In relation to this study 
findings, there were evident difference as they both seem to contradict based on their 
results. However, it is important to note that this study was consisting of both CKD and 
non CKD as well as Diabetic and Non diabetics. 
Hence, even though there were systematic reviews and met-analysis done on 
these direct head to head comparisons, PICO were quite distinct as most of them were 
based on CKD patients of stage 3 or more. However, their findings were similar that both 
RAS inhibitors as well as CCB can be good at reducing BP and UAE levels with no special 
reno-protective effect for ACEis or ARBs which contradicts other findings based on 
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previous literature except two (34,36,37,37).  
Study findings were also compared against individual trials that had head to head 
comparison. As for those with GFR as a CKD measure, ALLHAT trial (14.2%) had similar 
reduction in both the arms while other 3 studies showed ACE as favourable over CCB (41). 
However, it is quite important to note that ALLHAT trial had participants of 18102. 
Concerning those studies with UAE as a measure, one of 3 trials showed decrease in both 
but reduction in ACEi was slightly higher than CCB, while another trial showed that 
reduction was somewhat similar in both the regimens (40,42,104).  In addition, one study 
showed greater reduction for CCB than ARB arm. Nonetheless,it is indeed worth noting 
that this one trial that favoured CCB had only 20 participants which indirectly implies low 
statistical power of the study due to small sample size. Furthermore, ALL seven RCTs 
showed similar reduction in BP measurements for both the arms except for trial that 
indicated higher reduction in CCB over RAS but it only had 60 participants. 
In overall, trials were all in harmony with our findings and this possibly indicated 
that even though favoring RAS was not statistically different, there is greater support from 
existing literature for our findings to be clinically significant. Also, if meta-analysis was 
done with more studies, there seems to be chance of having statistical significance. 
5.2. Overall completeness and applicability of evidence 
Most of the trials were not reporting about all the times ranging from motality 
to BP difference post treatment. Also, studies did not report measures using unified 
method. However, studies had included high risk as well as low risk hypertensive patients.  
In addition, diabetes as well as non-diabetic patients were included. In 
addition, progression of CKD from all 1-4 stages were part of this review. All of this can, 
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consequently, can be addressed to any hypertensive patients with any CKD stage regardless 
of their diabetic status. Moreover, majority of the studies collated for this review does not 
report RR, HR or OR due to which complete, sensible and consistent conclusion cannot be 
drawn from this regard to study medications effects on outcome of our interest. However, 
with the available data, I had done an exploratory MA for determining the RR for CKD 
progression, Weighted mean differences in SBP as well as for DBP using IVhet model 
from MetaXL software. 
Finally yet importantly, Some studies had add on therapy in addition to randomly 
assigned study medications of our interest for which effect could be different than without 
add on therapy. Moreover, one of the studies despite of having more than 20% loss to 
follow up after random assignment but before analysis, they did not use intention to treat 
analysis. However, all their participants were considered who met inclusion criteria after 
removing the withdrawn participants for the analysis.  
5.3. Strengths of this study 
  Firstly,this study is quite novel in terms of its PICO which includes patients with 
any CKD stage from 1-4 amongst diabetic and non-diabetic population groups.. 
Furthermore, meta-analysis for primary as well as secondary outcomes in this study was 
executed using IVhet model, which is far better than conventional RE models that can 
cause over dispersion of the study effects.Since this meta-analysis was based on less than 
5 studies, using IVhet has certainly helped us produce as accurate as possible overall pooled 
estimate for our study outcomes. Moreover, using Doi plot also indicated proper 
assessment of publication bias as it is more optimal for MA with fewer studies and is more 
sensitive enough to detect better than funnel plot. Besides, most of the included studies had 
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large sample size which means that each of the included study had a higher statistical power 
to detect the differences between treatment arms. Also, we used PRISMA for reporting 
using PRISMA which enables replication by other researchers and more structured 
reporting pattern. .  
5.4. Limitations in the review 
This is undoubtedly a novel review that looks at effect of RAS blockers and CCB 
on the BP level as well as renal disease progression amongst diabetic as well as non diabetic 
hypertensive patients. However, this review has its own set of limitations. The included 
trials in this review have heterogeneity in terms of methods, BP measurement at baseline 
and BP target for the study, study populations and medications that will altogether increase 
the likelihood for potential limitations in the study. In addition, the study took account of 
sample size as small as 20, and studies with longer length of follow-up as less as 3 months, 
which implies that included studies, does not have sufficient statistical power to verify the 
summarised evidence.  
Due to insufficient number of studies with appropriate effect size such as HR, RR 
(or the required information to calculate those), meta analysis could not be done on all the 
studies included for Systematic review. As for those with which MA was done, subgroup 
analysis or meta-regression was not feasible due to the low number of included studies. 
Hence, I could not assess and address the heterogeneity. Additionally, the studies included 
were not necessarily the studies with outcomes of interest as I included any study that 
reported values for CKD outcome and BP measures. Moreover, the studies were quite 
heterogeneous with some studies with participants over 18,000 while the other included 
trial has only 20 participants, which again implies that this review is not sufficient to make 
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an inference for the effect of RAS vs CCB on BP measurements and progression of CKD. 
Furthermore, the dose variation was quite apparent across studies, which makes it less 
comparable despite of lack of difference seen in groups with high doses vs low doses. 
Finally yet importantly, estimation of GFR was evidently heterogeneous across studies and 
on top of that, few trials even did not mention how it was being calculated in their study. 
Apart from all that mentioned, due to the search strategy that included search terms for 
outcome, it is possible that I have missed to retrieve those studies that had CKD stage 1 or 
2 as some studies might have considered it as those with normal renal function and might 
not have defined it as CKD stage 1 or 2. 
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CHAPTER –6: CONCLUSION 
To sum up, this study evidence finds no benefit over the other. Both RAS 
antagonists and CCBs showed no statistically significant difference neither for primary 
CKD outcome nor in terms of secondary BP endpoints in the study. However, the study 
have its own set of limitations due to which more well designed and well conducted RCTs 
with robust findings are required to confirm the inferences based on this review. 
6.1. Implications for Practice 
Based on findings of this study, clinical practice can adopt either RAS blockers or CCBs 
as an intial therapy for hypertensive patients with any CKD stage from I-IV as there is no 
difference between both of those treatment regimens. 
6.2. Implications for Research 
Despite of the evidence indicating no difference between RAS blockers and 
CCBs, more number of well-designed and larger randomized controlled studies that are 
aimed at examining the effect of antihypertensive drugs on CKD outcomes, including both 
diabetic as well as non-diabetic patients, are required to confirm the findings of this review 
due to study limitations. 
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APPENDICES 
 
Appendix A: Search strings for each of the major databases 
1. PubMed 
(((((((calcium channel blocker*[Title/Abstract] OR Amlodipine[Title/Abstract] OR 
Diltiazem[Title/Abstract] OR Felodipine[Title/Abstract] OR Isradipine[Title/Abstract] 
OR Nicardipine[Title/Abstract] OR Nifedipine[Title/Abstract] OR 
Nisoldipine[Title/Abstract] OR lercadipine[Title/Abstract] OR 
Verapamil[Title/Abstract] OR diltiazem[Title/Abstract])) AND (angiotensin converting 
enzyme inhibitor*[Title/Abstract] OR Perindopril[Title/Abstract] OR 
Ramipril[Title/Abstract] OR Captopril[Title/Abstract] OR benazepril[Title/Abstract] 
OR trandolapril[Title/Abstract] OR fosinopril[Title/Abstract] OR 
Lisinopril[Title/Abstract] OR moexipril[Title/Abstract] OR enalapril[Title/Abstract])) 
OR (angiotensin recptor blocker*[Title/Abstract] OR losartan[Title/Abstract] OR 
valsartan[Title/Abstract] OR irbesartan[Title/Abstract] OR candesartan[Title/Abstract] 
OR telmisartan[Title/Abstract] OR eprosartan[Title/Abstract] OR 
olmesartan[Title/Abstract])) AND chronic kidney disease*[MeSH Terms]) OR 
(glomerular filtration rate[Title/Abstract] or GFR[Title/Abstract])) OR (Urinary albumin 
excretion[Title/Abstract] or UAE[Title/Abstract] or albuminuria[Title/Abstract])). Such 
was restricted to Humans and Study designs such as observational study and RCTs. 
2. Cochrane Library 
(calcium channel blockers OR CCBs OR amlodipine OR Diltiazem OR 
Felodipine OR Isradipine OR Nicardipine OR Nifedipine OR Nisoldipine OR lercadipine 
OR Verapamil OR diltiazem):ti,ab,kw AND (angiotensin-receptor-blocker OR ARBs 
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OR losartan OR valsartan OR irbesartan OR candesartan OR telmisartan OR eprosartan 
OR olmesartan):ti,ab,kw AND (angiotensin‐converting enzyme inhibitors OR ACEIs 
OR Perindopril OR Ramipril OR Captopril OR benazepril OR trandolapril OR fosinopril 
OR Lisinopril OR moexipril OR enalapril):ti,ab,kw 
3. Embase 
The search string used in this database that could retrieve relevant articles were 
(((('calcium'/exp OR calcium) AND channel AND blockers OR ccbs OR 
'amlodipine'/exp OR amlodipine OR 'felodipine'/exp OR felodipine OR 'isradipine'/exp 
OR isradipine OR 'nicardipine'/exp OR nicardipine OR 'nifedipine'/exp OR nifedipine 
OR 'nisoldipine'/exp OR nisoldipine OR lercadipine OR 'verapamil'/exp OR verapamil 
OR 'diltiazem'/exp OR diltiazem) AND ('angiotensin receptor blocker'/exp OR 
'angiotensin receptor blocker' OR arbs OR 'losartan'/exp OR losartan OR 'valsartan'/exp 
OR valsartan OR 'irbesartan'/exp OR irbesartan OR 'candesartan'/exp OR candesartan 
OR 'telmisartan'/exp OR telmisartan OR 'eprosartan'/exp OR eprosartan OR 
'olmesartan'/exp OR olmesartan) OR (angiotensin‐converting AND ('enzyme'/exp OR 
enzyme) AND ('inhibitors'/exp OR inhibitors)) OR aceis OR 'perindopril'/exp OR 
perindopril OR 'ramipril'/exp OR ramipril OR 'captopril'/exp OR captopril OR 
'benazepril'/exp OR benazepril OR 'trandolapril'/exp OR trandolapril OR 'fosinopril'/exp 
OR fosinopril OR 'lisinopril'/exp OR lisinopril OR 'moexipril'/exp OR moexipril OR 
'enalapril'/exp OR enalapril) AND ([controlled clinical trial]/lim OR [randomized 
controlled trial]/lim) AND ([article]/lim OR [article in press]/lim) AND [humans]/lim 
AND [clinical study]/lim AND ([embase]/lim OR [medline]/lim OR [pubmed-not-
medline]/lim) AND [2008-2018]/py AND [medline]/lim) AND ('clinical article'/de OR 
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'clinical study'/de OR 'clinical trial'/de OR 'clinical trial (topic)'/de OR 'comparative 
effectiveness'/de OR 'comparative study'/de OR 'controlled clinical trial'/de OR 
'controlled clinical trial (topic)'/de OR 'controlled study'/de OR 'crossover procedure'/de 
OR 'dosage schedule comparison'/de OR 'double blind procedure'/de OR 'drug dosage 
form comparison'/de OR 'drug dose comparison'/de OR 'evidence based medicine'/de OR 
'evidence based practice'/de OR 'experimental design'/de OR 'experimental study'/de OR 
'factorial design'/de OR 'good clinical practice'/de OR 'human'/de OR 'human 
experiment'/de OR 'intention to treat analysis'/de OR 'intervention study'/de OR 'major 
clinical study'/de OR 'meta analysis'/de OR 'meta analysis (topic)'/de OR 'multicenter 
study'/de OR 'multicenter study (topic)'/de OR 'normal human'/de OR 'open study'/de OR 
'outcomes research'/de OR 'parallel design'/de OR 'phase 1 clinical trial'/de OR 'phase 2 
clinical trial'/de OR 'phase 3 clinical trial'/de OR 'phase 4 clinical trial'/de OR 
'randomized controlled trial'/de OR 'randomized controlled trial (topic)'/de OR 'single 
blind procedure'/de OR 'study design'/de OR 'systematic review'/de) AND ([adult]/lim 
OR [aged]/lim OR [middle aged]/lim OR [very elderly]/lim OR [young adult]/lim) AND 
('amlodipine'/dd OR 'amlodipine besylate'/dd OR 'amlodipine camsylate' OR 'amlodipine 
plus atenolol'/dd OR 'amlodipine plus hydrochlorothiazide'/dd OR 'amlodipine plus 
metoprolol' OR 'angiotensin 1 receptor antagonist'/dd OR 'angiotensin 2 receptor 
antagonist'/dd OR 'angiotensin receptor antagonist'/dd OR 'antihypertensive agent'/dd 
OR 'atorvastatin'/dd OR 'azelnidipine'/dd OR 'benazapril' OR 'benazepril'/dd OR 
'benazepril plus hydrochlorothiazide'/dd OR 'benidipine'/dd OR 'benzodiazepine'/dd OR 
'benzodiazepine derivative'/dd OR 'calcium channel blocking agent'/dd OR 'calcium 
channel blocking agent receptor'/dd OR 'candesartan'/dd OR 'candesartan hexetil'/dd OR 
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'candesartan hexetil plus hydrochlorothiazide'/dd OR 'cilazapril'/dd OR 'cilazapril plus 
hydrochlorothiazide'/dd OR 'cilnidipine'/dd OR 'delapril'/dd OR 'dihydropyridine'/dd OR 
'dihydropyridine derivative'/dd OR 'diltiazem'/dd OR 'enalapril'/dd OR 'enalapril maleate 
plus hydrochlorothiazide'/dd OR 'enalapril plus hydrochlorothiazide'/dd OR 'enalopril' 
OR 'eprosartan'/dd OR 'felodipine'/dd OR 'felodipine plus ramipril'/dd OR 'fimasartan'/dd 
OR 'hydrochlorothiazide plus irbesartan'/dd OR 'hydrochlorothiazide plus lisinopril'/dd 
OR 'hydrochlorothiazide plus losartan'/dd OR 'hydrochlorothiazide plus losartan plus 
amlodipine' OR 'hydrochlorothiazide plus olmesartan'/dd OR 'hydrochlorothiazide plus 
quinapril'/dd OR 'hydrochlorothiazide plus telmisartan'/dd OR 'hydrochlorothiazide plus 
valsartan'/dd OR 'hydrochlorothiazide, lisinopril drug combination' OR 
'hydrochlorthiazide plus valsartan' OR 'imidapril'/dd OR 'indapamide plus perindopril'/dd 
OR 'irbesartan'/dd OR 'irbesartan plus amlodipine' OR 'lisinopril'/dd OR 'lisinopril plus 
amlodipine' OR 'lisinopril plus manidipine' OR 'losartan'/dd OR 'manidipine'/dd OR 
'nanopril' OR 'nicardipine'/dd OR 'nifedipine'/dd OR 'nimodipine'/dd OR 'nisoldipine'/dd 
OR 'nitrendipine'/dd OR 'olanzapine'/dd OR 'olmesartan'/dd OR 'olmesartan plus 
atenolol' OR 'peduopril' OR 'perindopril'/dd OR 'perindopril plus lindapamide' OR 
'perindopril tert butylamine'/dd OR 'pitavastatin'/dd OR 'pravastatin'/dd OR 'prescription 
drug'/dd OR 'quinapril'/dd OR 'ramipril'/dd OR 'renin'/dd OR 'renin angiotensin system 
blocking drug' OR 'renin angiotensin system inhibitor'/dd OR 'renin inhibitor'/dd OR 
'rilmenidine'/dd OR 'sacubitril'/dd OR 'telmisartan'/dd OR 'ticlopidine'/dd OR 
'trandolapril'/dd OR 'trandolapril plus verapamil'/dd OR 'valnidipine' OR 'valsartan'/dd 
OR 'verapamil'/dd.   
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Appendix B: Table for Detailed Description of Included Studies 
Agodoa et al, 2001 
Methods A randomized, doubleblind, 3x2 factorial trial  
Participants Non-diabetic African Americans who were aged 18 to 70 years 
with glomerular filtration rate [GFR] of 20-65 mL/min per 1.73 m2 
and no other diagnosed causes for renal impairment. Individuals 
with DBP <95mmHg, Urinary protein to creatinine ratio greater 
than 2.5, malignant HTN within 6 months, identified non BP related 
causes for renal disease, serious systemic disease, history of heart 
failure and those with specific indication to study drug were 
excluded. 
 
Interventions Amlodipine (5 to 10mg/d), Ramipril (2.5 to 10 mg/d) or metoprolol 
( 50 to 200 mg/d) 
Outcomes The primary outcome measure was the rate of change in GFR; the 
main secondary outcome was a composite index of the clinical end 
points of reduction in 
GFR of more than 50% or 25 mL/min per 1.73 m2, end-stage renal 
disease, or death. 
Notes Additional unmasked drugs such as furosemide, doxazosin 
mesylate, clonidine hydrochloride, hydralazine hydrochloride and 
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minoxidil were given if BP goal was not achieved with randomly 
assigned treatment. 
 
Herlitz et al, 2001 
Methods Open long-term randomized prospective multicenter study with 28 
centers in Sweden, UK, Germany, France and Israel. 
Participants Non diabetic patients who are aged 18-74 years with uncontrolled 
HTN and are  on treatment with a diuretic and beta blocker were 
included in the study. Individuals with History of Heart diseases, 
diabetes, renal transplantation, known bladder dysfunction, 
nephrectomy and those on corticosteroids, steroidal anti-
inflammatory and immunosuppressive drugs, as well as those with 
known intolerance to ACEi or CCB were excluded from the study. 
Interventions Ramipril (2.5-20mg/d), Felodipine (2.5-20mg/d) and half doses in 
combination group of Ramipril with Felodipine 
Outcomes Change in BP control and progression of renal insufficiency 
Notes Follow up of 1.73 years on average based on three groups 
 
Fogari et al, 2002 
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Methods Multicenter, open labeled, randomized, prospective, parallel group 
study which started with 4 week placebo washout period for the 
selected participants, checked them for inclusion criteria using 
computerized randomization by an external investigator who is not 
part of participants’ recruitment, assigned interventions such 
monotherapy of ACEi and CCBs as well as combination therapy of 
both during 3 month titration period. People with side effects or 
non-responders discontinued and rest of the patients being enrolled 
and was followed over 4 years. BP being monitored monthly for 
first three months for three times with 5 minutes rest and its average 
were taken as their BP level. Patients were then checked every 6 
months for BP and UAE levels, which was assessed by 
radioimmunoassay. 
Participants Outpatients including both the genders, with essential hypertension, 
Diabetes mellitus (type 1), microalbuminuric with 30-300mg/24hr 
in two different 24-h urine collections taken 7 days prior to 
enrollment, BMI<30 kg/m2 and Serum creatinine <1.5mg/Dl. 
Patients with history of CVD and Cancer, total cholesterol >240 
mg/dL, ECG showing left ventricular hypertrophy and those who 
smoke as well as those using Diuretics or Beta blockers were 
excluded from the study. 
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Interventions Amlodipine (5 to 15 mg/day), Fosinopril (10 to 30 mg/day), and 
Amlodipine with fosinopril  (5/10 to 15/30 mg/day) 
Outcomes Changes on BP and Microalbuminuria as well as cardiovascular 
outcomes 
Notes Patients were on diabetes control either by diet, metformin or 
metformin with sulfonylurea which could act as co-intervention.  
Adverse events were found to be more or less same in both the 
groups. 
 
Leneen et al, 2006 
Methods Randomized trial with intention to treat analysis and statistical 
methods using z test for continuous variables and contingency table 
analysis for categorical values, cumulative event rates based on 
Kaplan Meier and Cox proportional model for estimation of 
Hazards ratios. 
Participants Participants aged greater than or equal to 55 years, with untreated 
or treated HTN and diabetes, and with at least one risk factor for 
CHD were included for the study. 
Interventions Amlodipine (2.5,5 and 10 mg/d) and Lisinopril (10,20 and 40mg/d) 
Outcomes The primary outcome was combined fatal coronary heart disease or 
nonfatal myocardial infarction, analyzed by intention-to-treat. 
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Secondary outcomes included all-cause mortality, stroke, combined 
cardiovascular disease (CVD), end-stage renal disease (ESRD), 
cancer, and gastrointestinal bleeding. 
Notes If study drugs were not able to achieve BP target, step 2 drugs such 
as atenolol, clonidine or reserpine or step 3 drug such as 
hydrazaline will be given if needed. 
 
Ogihara et al, 2008 
Methods A prospective, randomized, open label study with blinded 
assessment of the endpoint and analysis done using incidence 
proportions with the help of Kaplan Meier Method and comparison 
made based on log rank test and cox regression analysis for 
estimating Hazard ratios. 
Participants Diabetic Patients with high-risk HTN aged <70 years were joined in 
the study.  
Interventions Candesartan cilexitil (4- 8 mg/d) and Amlodipine besylate (2.5-
5.0mg/d) 
Outcomes Primary end points including Sudden death which is unexpected 
death that happened within 24 hours without external causes; 
Cerebrovascular events including stroke or transient ischemic 
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attack; Cardiac events such as  heart failure, angina pectoris, or 
acute myocardial infarction; Renal events such as serum creatinine 
concentration 4.0 mg/dL, doubling of the serum creatinine 
concentration (however, creatinine 2.0 mg/dL is not regarded as an 
event), or end-stage renal disease, and Vascular events like 
dissecting aortic aneurysm or arteriosclerotic occlusion of a 
peripheral artery. 
Secondary and pre-specified end points are All-cause deaths, New-
onset of diabetes and stopping of treatment sue to adverse events 
Notes Candesartan cilexitil is increased to dose of 12 mg/d when 
necessary and Amlodipine besylate can be increased to the dose of 
10mg/d when necessary. 
 
Liakos et al, 2012 
Methods A prospective trial with analysis done using students’ t test or non-
parametric test for continuous variates and Chisquare or fishers test 
for categorical variates and a general linear model for multivariate 
analysis of covariance 
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Participants Non-diabetic Caucasian patients, aged 30–65 years, with 
uncomplicated and never treated hypertension, were included in this 
study.  
Interventions Irbesartan (300mg/d) and Diltiazem (300mg/d) 
Outcomes Effect on the inflammatory and thrombotic response 
Notes Renal  outcomes was none of their study outcomes due to which 
renal function was ascertained based on the GFR estimate given at 
baseline and end of the follow-up. Also, in case of drugs, diuretics 
(Hydrochlorothiazide with dose of 25mg/d) will be given if needed 
 
Ay. Et al, 2013 
Methods Randomized trial with analysis done using ANCOVA and Pearson 
correlation 
Participants Newly diagnosed hypertensive patients applying to the internal 
medicine and cardiology outpatient clinics with n=20 were included 
in the study and Patients with any damaged organ due to HTN 
diabetes, alcohol intake, smoking habits and those on any 
medications were excluded. 
Interventions Valsartan (80–320 mg/day) or Amlodipine (5–10 mg/day) 
Outcomes Changes on BP and Microalbuminuria  
Notes Patient of two groups were matched for age and BMI. 
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Appendix C: PRISMA checklist 
Section/topic  # Checklist item  Reported on page # 
TITLE  
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT  
Structured 
summary  
2 Provide a structured summary including, as applicable: background; objectives; data 
sources; study eligibility criteria, participants, and interventions; study appraisal and 
synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number.  
3&4 
INTRODUCTION  
Rationale  3 Describe the rationale for the review in the context of what is already known.  15&16 
Objectives  4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS).  
17 
METHODS  
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and, if available, provide registration information including registration 
number.  
NIL 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as criteria for 
eligibility, giving rationale.  
28-30 
Information 
sources  
7 Describe all information sources (e.g., databases with dates of coverage, contact with 
study authors to identify additional studies) in the search and date last searched.  
25-26 
Search  8 Present full electronic search strategy for at least one database, including any limits 
used, such that it could be repeated.  
85-89 
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Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic 
review, and, if applicable, included in the meta-analysis).  
25-30 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators.  
33-36 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) 
and any assumptions and simplifications made.  
25-38 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how this 
information is to be used in any data synthesis.  
36-37 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, difference in means).  32-36,37-38 
Synthesis of 
results  
14 Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (e.g., I2) for each meta-analysis.  
37-38 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies).  
37-38 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified.  
38 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons 
for exclusions at each stage, ideally with a flow diagram.  
39-
40 
Study 
characteristics  
18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-
up period) and provide the citations.  
41-
48 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 
12).  
47-
49 
Results of 
individual studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
50-
61 
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Synthesis of 
results  
21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
50-
61 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  50-
61 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression 
[see Item 16]).  
N/A 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main outcome; consider 
their relevance to key groups (e.g., healthcare providers, users, and policy makers).  
66-
71 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias).  
71-
72 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for 
future research.  
73 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
38 
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